<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="17990"><DrugName>pralatrexate</DrugName><DrugNamesKey><Name id="43101179">Difolta</Name><Name id="42913892">Folotyn</Name><Name id="42810475">pralatrexate</Name></DrugNamesKey><DrugSynonyms><Name><Value>10-propargyl-10-deazaaminopterin</Value></Name><Name><Value>DHFR inhibitor (anticancer), Allos</Value></Name><Name><Value>DHFR inhibitor (anticancer), Memorial Sloan-Kettering</Value></Name><Name><Value>pralatrexate</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>PDX, Allos</Value></Name><Name><Value>Folotyn</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Difolta</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>146464-95-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20234">SRI International</CompanyOriginator><CompaniesPrimary><Company id="29750">Baxter Oncology GmbH</Company><Company id="1045514">Mundipharma International Corp Ltd</Company><Company id="22730">Servier Canada Inc</Company><Company id="1179286">Acrotech Biopharma LLC</Company></CompaniesPrimary><CompaniesSecondary><Company id="20226">Southern Research Institute</Company><Company id="20234">SRI International</Company><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><Company id="23253">Allos Therapeutics Inc</Company><Company id="24232">Spectrum Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="17990" type="Drug"><TargetEntity id="199355" type="siDrug">Pralatrexate</TargetEntity></SourceEntity><SourceEntity id="1045514" type="Company"><TargetEntity id="5035938515" type="organizationId">Mundipharma International Corp Ltd</TargetEntity></SourceEntity><SourceEntity id="1179286" type="Company"><TargetEntity id="5067512915" type="organizationId">Acrotech Biopharma LLC</TargetEntity></SourceEntity><SourceEntity id="20226" type="Company"><TargetEntity id="4296384103" type="organizationId">Southern Research Institute</TargetEntity></SourceEntity><SourceEntity id="20234" type="Company"><TargetEntity id="4296599682" type="organizationId">SRI International</TargetEntity></SourceEntity><SourceEntity id="22122" type="Company"><TargetEntity id="4296508772" type="organizationId">Memorial Sloan-Kettering Cancer Center</TargetEntity></SourceEntity><SourceEntity id="22730" type="Company"><TargetEntity id="5035523703" type="organizationId">Servier Canada Inc</TargetEntity></SourceEntity><SourceEntity id="23253" type="Company"><TargetEntity id="4295912443" type="organizationId">Allos Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="24232" type="Company"><TargetEntity id="4295907365" type="organizationId">Spectrum Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="29750" type="Company"><TargetEntity id="4297886212" type="organizationId">Baxter Oncology GmbH</TargetEntity></SourceEntity><SourceEntity id="1011" type="ciIndication"><TargetEntity id="C15" type="ICD10"></TargetEntity><TargetEntity id="150" type="ICD9"></TargetEntity><TargetEntity id="10061882" type="MEDDRA"></TargetEntity><TargetEntity id="D004938" type="MeSH"></TargetEntity><TargetEntity id="-1694229607" type="omicsDisease"></TargetEntity><TargetEntity id="598" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1240" type="ciIndication"><TargetEntity id="C45" type="ICD10"></TargetEntity><TargetEntity id="163" type="ICD9"></TargetEntity><TargetEntity id="10027406" type="MEDDRA"></TargetEntity><TargetEntity id="D008654" type="MeSH"></TargetEntity><TargetEntity id="50251" type="ORPHANET"></TargetEntity><TargetEntity id="-666440137" type="omicsDisease"></TargetEntity><TargetEntity id="2015" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"></TargetEntity><TargetEntity id="D002289" type="MeSH"></TargetEntity><TargetEntity id="-1730468577" type="omicsDisease"></TargetEntity><TargetEntity id="612" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="127" type="ciIndication"><TargetEntity id="C16" type="ICD10"></TargetEntity><TargetEntity id="151" type="ICD9"></TargetEntity><TargetEntity id="10017758" type="MEDDRA"></TargetEntity><TargetEntity id="D013274" type="MeSH"></TargetEntity><TargetEntity id="-2031094615" type="omicsDisease"></TargetEntity><TargetEntity id="646" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1745" type="ciIndication"><TargetEntity id="C82" type="ICD10"></TargetEntity><TargetEntity id="D008224" type="MeSH"></TargetEntity><TargetEntity id="-1402578461" type="omicsDisease"></TargetEntity><TargetEntity id="1742" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1749" type="ciIndication"><TargetEntity id="C83.3" type="ICD10"></TargetEntity><TargetEntity id="10012818" type="MEDDRA"></TargetEntity><TargetEntity id="D016403" type="MeSH"></TargetEntity><TargetEntity id="544" type="ORPHANET"></TargetEntity><TargetEntity id="-308083648" type="omicsDisease"></TargetEntity><TargetEntity id="1741" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1753" type="ciIndication"><TargetEntity id="C84.4" type="ICD10"></TargetEntity><TargetEntity id="10034623" type="MEDDRA"></TargetEntity><TargetEntity id="D016411" type="MeSH"></TargetEntity><TargetEntity id="-585182853" type="omicsDisease"></TargetEntity><TargetEntity id="3114" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1754" type="ciIndication"><TargetEntity id="D016410" type="MeSH"></TargetEntity><TargetEntity id="836" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"></TargetEntity><TargetEntity id="10028228" type="MEDDRA"></TargetEntity><TargetEntity id="D009101" type="MeSH"></TargetEntity><TargetEntity id="29073" type="ORPHANET"></TargetEntity><TargetEntity id="-18870694" type="omicsDisease"></TargetEntity><TargetEntity id="710" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2243" type="ciIndication"><TargetEntity id="C57.0" type="ICD10"></TargetEntity><TargetEntity id="10016180" type="MEDDRA"></TargetEntity><TargetEntity id="D005185" type="MeSH"></TargetEntity><TargetEntity id="-33569282" type="omicsDisease"></TargetEntity><TargetEntity id="600" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3083" type="ciIndication"><TargetEntity id="C48" type="ICD10"></TargetEntity><TargetEntity id="10061344" type="MEDDRA"></TargetEntity><TargetEntity id="D010534" type="MeSH"></TargetEntity><TargetEntity id="-745704479" type="omicsDisease"></TargetEntity><TargetEntity id="633" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="316" type="ciIndication"><TargetEntity id="10003899" type="MEDDRA"></TargetEntity><TargetEntity id="-1829786210" type="omicsDisease"></TargetEntity><TargetEntity id="699" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="319" type="ciIndication"><TargetEntity id="10029547" type="MEDDRA"></TargetEntity><TargetEntity id="D008228" type="MeSH"></TargetEntity><TargetEntity id="547" type="ORPHANET"></TargetEntity><TargetEntity id="-1008757452" type="omicsDisease"></TargetEntity><TargetEntity id="703" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3466" type="ciIndication"><TargetEntity id="4580" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="623" type="ciIndication"><TargetEntity id="C76.0" type="ICD10"></TargetEntity><TargetEntity id="10067821" type="MEDDRA"></TargetEntity><TargetEntity id="D006258" type="MeSH"></TargetEntity><TargetEntity id="-545944758" type="omicsDisease"></TargetEntity><TargetEntity id="1148" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"></TargetEntity><TargetEntity id="10033128" type="MEDDRA"></TargetEntity><TargetEntity id="D010051" type="MeSH"></TargetEntity><TargetEntity id="-1370909262" type="omicsDisease"></TargetEntity><TargetEntity id="626" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="135" type="Action"><TargetEntity id="413" type="Mechanism">Dihydrofolate Reductase (DHFR) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="665" type="Action"><TargetEntity id="1044" type="Mechanism">Folate Antagonists</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="PTGT-08059" type="ciTarget"><TargetEntity id="3551288865733" type="siTarget">Folate transporter 1</TargetEntity><TargetEntity id="-1071862734" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Peripheral T-cell lymphoma - US - Oct-2009</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1753">Peripheral T-cell lymphoma</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1011">Esophagus tumor</Indication><Indication id="1240">Mesothelioma</Indication><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="127">Stomach tumor</Indication><Indication id="1745">Follicle center lymphoma</Indication><Indication id="1749">Diffuse large B-cell lymphoma</Indication><Indication id="1754">Cutaneous T-cell lymphoma</Indication><Indication id="1828">Multiple myeloma</Indication><Indication id="2243">Fallopian tube cancer</Indication><Indication id="3083">Peritoneal tumor</Indication><Indication id="316">B-cell lymphoma</Indication><Indication id="319">Non-Hodgkin lymphoma</Indication><Indication id="3466">Metastatic bladder cancer</Indication><Indication id="49">Breast tumor</Indication><Indication id="623">Head and neck tumor</Indication><Indication id="651">Cancer</Indication><Indication id="725">Solid tumor</Indication><Indication id="799">Ovary tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="665">Folate receptor antagonist</Action><Action id="43954">Folate transporter 1 modulator</Action><Action id="135">DHFR inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="1589">Apoptosis stimulator</Action></ActionsSecondary><Technologies><Technology id="746">Solution</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="740">Infusion</Technology></Technologies><LastModificationDate>2019-06-18T11:48:18.000Z</LastModificationDate><ChangeDateLast>2019-03-06T00:00:00.000Z</ChangeDateLast><AddedDate>1998-06-08T09:43:18.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Former licensee &lt;ulink linkID="23253" linkType="Company"&gt;Allos Therapeutics&lt;/ulink&gt; (a subsidiary of  &lt;ulink linkID="24232" linkType="Company"&gt;Spectrum Pharmaceuticals&lt;/ulink&gt;) and &lt;ulink linkID="1045514" linkType="Company"&gt;Mundipharma&lt;/ulink&gt;, under license from &lt;ulink linkID="22122" linkType="Company"&gt;Memorial Sloan-Kettering Cancer Center&lt;/ulink&gt;,  &lt;ulink linkID="20234" linkType="Company"&gt;SRI International&lt;/ulink&gt; and  &lt;ulink linkID="20226" linkType="Company"&gt;Southern Research Institute&lt;/ulink&gt;, has developed and launched an iv formulation of pralatrexate  (10-propargyl-10-deazaaminopterin (PDX); Folotyn; Difolta), an antifolate that targets dihydrofolate reductase and has high affinity for reduced folate carrier type-1 oncoprotein. The product is indicated in the US, and currently marketed by &lt;ulink linkID="1179286" linkType="Company"&gt;Acrotech BioPharma&lt;/ulink&gt; (a subsidiary of &lt;ulink linkID="30215" linkType="Company"&gt;Aurobindo Pharma)&lt;/ulink&gt;, for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) [&lt;ulink linkID="1047619" linkType="Reference"&gt;1047619&lt;/ulink&gt;]. In Japan, it is indicated for   the treatment of recurrent or refractory PTCL [&lt;ulink linkID="1943180" linkType="Reference"&gt;1943180&lt;/ulink&gt;].    &lt;/para&gt;&lt;para&gt;In October 2009, pralatrexate was launched in the US for relapsed or refractory  PTCL, following accelerated approval [&lt;ulink linkID="1047183" linkType="Reference"&gt;1047183&lt;/ulink&gt;]; full-scale launch commenced in January 2010  [&lt;ulink linkID="1078524" linkType="Reference"&gt;1078524&lt;/ulink&gt;]. In August 2017, the product was launched in Japan for recurrent or refractory PTCL [&lt;ulink linkID="1962812" linkType="Reference"&gt;1962812&lt;/ulink&gt;].   In October 2015, a dose-finding phase I trial began  to assess pralatrexate in combination with CHOP regimen in newly diagnosed PTCL [&lt;ulink linkID="2074710" linkType="Reference"&gt;2074710&lt;/ulink&gt;]; in March 2017, the trial was ongoing and a   phase III trial of the combination  for first-line PTCL was expected to be planned once the proper dose of the combination would be determined. Both trial concepts were designed to also fulfill the FDA's postmarketing requirements under the accelerated approval [&lt;ulink linkID="1908613" linkType="Reference"&gt;1908613&lt;/ulink&gt;]; in March 2018, the phase I trial was ongoing [&lt;ulink linkID="2011720" linkType="Reference"&gt;2011720&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Allos and Mundipharma, which was formerly a licensee in  European,  were previously developing the drug for  PTCL in Europe. By December 2010, an MAA had been filed and accepted for review in the EU for relapsed or refractory PTCL [&lt;ulink linkID="1157245" linkType="Reference"&gt;1157245&lt;/ulink&gt;]; however, in January 2012, the CHMP recommended against conditional approval  [&lt;ulink linkID="1256450" linkType="Reference"&gt;1256450&lt;/ulink&gt;], [&lt;ulink linkID="1256468" linkType="Reference"&gt;1256468&lt;/ulink&gt;]; at that time, Allos  filed a request for re-examination of the negative opinion [&lt;ulink linkID="1258571" linkType="Reference"&gt;1258571&lt;/ulink&gt;]. In April 2012, the CHMP reaffirmed the negative opinion [&lt;ulink linkID="1282299" linkType="Reference"&gt;1282299&lt;/ulink&gt;], [&lt;ulink linkID="1282274" linkType="Reference"&gt;1282274&lt;/ulink&gt;];   in June 2012, the EC recommended against approval; the decision was final and binding [&lt;ulink linkID="1398317" linkType="Reference"&gt;1398317&lt;/ulink&gt;]. In May 2013, Spectrum regained rights in Europe from Mundipharma    [&lt;ulink linkID="1534042" linkType="Reference"&gt;1534042&lt;/ulink&gt;]; however, no further development has since been reported. &lt;/para&gt;&lt;para&gt;The company was previously developing the drug in other cancer settings, including mesothelioma,  multiple myeloma (MM), cutaneous T-cell lymphoma (CTCL), advanced bladder cancer,  B-cell lymphoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), stomach cancer, breast cancer, ovarian, fallopian and primary peritoneal cancer. By January 2001, phase II  trials had been initiated for mesothelioma [&lt;ulink linkID="495177" linkType="reference"&gt;495177&lt;/ulink&gt;], [&lt;ulink linkID="475651" linkType="Reference"&gt;475651&lt;/ulink&gt;]; however, this indication was not listed on the company's January 2008 pipeline and no further development has been reported [&lt;ulink linkID="907518" linkType="Reference"&gt;907518&lt;/ulink&gt;]. In August 2010, a phase I/II study of &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; and pralatrexate in patients with recurrent platinum-sensitive ovarian, fallopian or primary peritoneal cancer was initiated; in July 2017, the trial was completed [&lt;ulink linkID="1198485" linkType="Reference"&gt;1198485&lt;/ulink&gt;]; however, no further development has since been reported. In August 2011, a phase I trial was ongoing for solid tumors; however, no further development has been reported since that time   [&lt;ulink linkID="1198465" linkType="Reference"&gt;1198465&lt;/ulink&gt;]. In August 2010, a phase I multiple myeloma in combination with &lt;ulink linkID="15954" linkType="Drug"&gt;bortezomib&lt;/ulink&gt; was initiated; in August 2014, the trial was ongoing [&lt;ulink linkID="1110266" linkType="Reference"&gt;1110266&lt;/ulink&gt;].      In February 2014,  phase I trials in CTCL  were ongoing  [&lt;ulink linkID="1105201" linkType="Reference"&gt;1105201&lt;/ulink&gt;]. In March 2011, a phase II trial  in  advanced bladder cancer was ongoing [&lt;ulink linkID="1119663" linkType="Reference"&gt;1119663&lt;/ulink&gt;]; in June 2012, data were presented [&lt;ulink linkID="1295791" linkType="Reference"&gt;1295791&lt;/ulink&gt;]. In September 2009, a phase II trial in B-cell lymphomas was initiated; in February 2014, the trial was ongoing [&lt;ulink linkID="1105201" linkType="Reference"&gt;1105201&lt;/ulink&gt;]. In August 2010, a phase II study in HNSCC was initiated; in April 2014, the trial was completed [&lt;ulink linkID="1198487" linkType="Reference"&gt;1198487&lt;/ulink&gt;]. In  October 2010, data from a phase IIb study in NSCLC were reported [&lt;ulink linkID="1137890" linkType="Reference"&gt;1137890&lt;/ulink&gt;]. In January 2011, Allos reported it would not be pursuing phase III trials for NSCLC [&lt;ulink linkID="1160474" linkType="Reference"&gt;1160474&lt;/ulink&gt;]. In July 2010, a phase II study of pralatrexate plus &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; in patients with advanced esophageal and gastroesophageal carcinoma was initiated; in November 2013, the trial was ongoing [&lt;ulink linkID="1198478" linkType="Reference"&gt;1198478&lt;/ulink&gt;].  In September 2010, a phase II trial of pralatrexate plus &lt;ulink linkID="3792" linkType="Drug"&gt;oxaliplatin&lt;/ulink&gt; in unresectable or metastatic esophageal, stomach or gastroesophageal junction cancer was initiated [&lt;ulink linkID="1198479" linkType="Reference"&gt;1198479&lt;/ulink&gt;].   In March  2011, a phase  II breast cancer study was recruiting and  interim  data were expected in 2H11 [&lt;ulink linkID="1174013" linkType="Reference"&gt;1174013&lt;/ulink&gt;]. No further development for any of these indications has been reported.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In September 2009, following the approval of pralatrexate for  relapsed or refractory peripheral  PTCL, the agent received seven years of orphan drug exclusivity for that indication, which was due to expire  inSeptember 2016 [&lt;ulink linkID="1174013" linkType="Reference"&gt;1174013&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Memorial Sloan-Kettering was issued &lt;ulink linkID="IN2433021" linkType="Patent"&gt;WO-9802163&lt;/ulink&gt; and &lt;ulink linkID="IN2721733" linkType="Patent"&gt;US-06028071&lt;/ulink&gt;, entitled "Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors." Highly purified pralatrexate compositions tested in xenograft models were shown to be superior to methotrexate and were even superior to the newer clinical candidate &lt;ulink linkID="3012" linkType="Drug"&gt;edatrexate&lt;/ulink&gt;. Moreover, pralatrexate showed the ability to cure tumors such that there was no evidence of tumor growth several weeks after the cessation of therapy [&lt;ulink linkID="420162" linkType="reference"&gt;420162&lt;/ulink&gt;]. In October 2012, the USPTO granted a 5-year extension to  &lt;ulink linkID="IN2721733" linkType="Patent"&gt;US-06028071&lt;/ulink&gt;, extending the expiration date from July 16, 2017 to July 16, 2022 [&lt;ulink linkID="1329370" linkType="Reference"&gt;1329370&lt;/ulink&gt;].  &lt;ulink linkID="PA3065144" linkType="Patent"&gt;US-07622470&lt;/ulink&gt; was issued in November 2009, covering the use of pralatrexate  for the treatment of T-cell lymphoma [&lt;ulink linkID="1060814" linkType="Reference"&gt;1060814&lt;/ulink&gt;]. In March 2011, Allos stated that licensed patents and applications covering  pralatrexate were due to expire at various times between July 2017 and May 2025 [&lt;ulink linkID="1174013" linkType="Reference"&gt;1174013&lt;/ulink&gt;]. In March 2012, Allos stated that the drug's  patent portfolio consists of four issued US patent, two granted European patents, single granted patents in each of Australia, Canada, Mexico, Indonesia, Singapore and South Africa, two granted  New Zealand patents and pending patent applications in the US, Canada, Europe, Japan, China, Brazil, South Korea, Mexico, Norway,  the Philippines and in the International Bureau of WIPO; patents and applications are predicted to expire at between July 2017 and August 2031 [&lt;ulink linkID="1277231" linkType="Reference"&gt;1277231&lt;/ulink&gt;]. In February 2013, Spectrum stated that the composition of matter patent in Europe would expire in 2017, but that it was eligible for extension following regulatory approval in Europe; at that time, several patent applications were pending in the US and elsewhere, claiming different uses of pralatrexate [&lt;ulink linkID="1398317" linkType="Reference"&gt;1398317&lt;/ulink&gt;]. In March 2014, several patent applications were still pending. At that time, patents covering pralatrexate for PTCL were due to expire in 2025 [&lt;ulink linkID="1534042" linkType="Reference"&gt;1534042&lt;/ulink&gt;]; in March 2017, that was still the case [&lt;ulink linkID="1908613" linkType="Reference"&gt;1908613&lt;/ulink&gt;]. The composition of matter patent in Europe expired in 2017. By  March 2018, Spectrum had filed  for an extension to the Japanese patent  covering the use of the drug  for PTCL, which if granted, it would extend the patent term by approximately 3 years and 11 months. At that time, the company also noted that the use patent was eligible for similar patent term extension in Europe following regulatory approval [&lt;ulink linkID="2011720" linkType="Reference"&gt;2011720&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2014, Spectrum filed suit in the US District Court against &lt;ulink linkID="20348" linkType="Company"&gt;Teva Pharmaceuticals&lt;/ulink&gt;, &lt;ulink linkID="28696" linkType="Company"&gt;Sandoz&lt;/ulink&gt;, &lt;ulink linkID="27814" linkType="Company"&gt;Fresenius Kabi&lt;/ulink&gt;,  &lt;ulink linkID="29387" linkType="Company"&gt;Dr Reddy's Laboratories Ltd&lt;/ulink&gt; and &lt;ulink linkID="29387" linkType="Company"&gt;Dr Reddy's Laboratories Inc&lt;/ulink&gt; in response to their four separate ANDAs with Paragraph IV certifications for generic versions of the drug; the trial was set for September 2016 [&lt;ulink linkID="1642808" linkType="Reference"&gt;1642808&lt;/ulink&gt;].  By July 2016, litigations with Teva Pharmaceuticals, Sandoz,  Dr Reddy's Laboratories Ltd and Dr Reddy's Laboratories Inc had been settled; at that time, the litigation with Fresenius Kabi was settled and generic versions of pralatrexate would not be permitted to be marketed in the US until November 15, 2022 [&lt;ulink linkID="1780089" linkType="Reference"&gt;1780089&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Peripheral T-cell lymphoma&lt;/subtitle&gt;In March 2011, the design of a phase III trial in previously untreated PTCL patients was agreed upon with the FDA under an SPA, providing agreement that the trial design would be sufficient for a regulatory submission in the first-line setting; the trial could also support the conversion of the accelerated approval in previously treated patients to a full approval. At that time the trial was expected to begin in 2011 [&lt;ulink linkID="1172974" linkType="Reference"&gt;1172974&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2006, the FDA granted Orphan Drug status  for T-cell lymphoma and in October 2006, the FDA granted the drug Fast Track status for T-cell lymphoma [&lt;ulink linkID="720943" linkType="Reference"&gt;720943&lt;/ulink&gt;], [&lt;ulink linkID="680196" linkType="Reference"&gt;680196&lt;/ulink&gt;]. In May 2008,  an NDA filing was planned for PTCL  [&lt;ulink linkID="903507" linkType="Reference"&gt;903507&lt;/ulink&gt;]. In  March 2009, the company filed an NDA for patients with relapsed or refractory PTCL and requested a priority review [&lt;ulink linkID="994735" linkType="Reference"&gt;994735&lt;/ulink&gt;]. In May 2009, the FDA accepted the NDA for review and granted the application Priority Review status [&lt;ulink linkID="1012588" linkType="Reference"&gt;1012588&lt;/ulink&gt;]. In September 2009, the Oncologic Drugs Advisory Committee voted 10-to-4 that the response rate and duration of response observed with pralatrexate were likely to predict clinical benefit in patients with relapsed or refractory PTCL, and recommended accelerated approval of the drug [&lt;ulink linkID="1039226" linkType="Reference"&gt;1039226&lt;/ulink&gt;]. In September 2009, an accelerated approval was granted for PTCL. In connection with the approval, Allos agreed to conduct additional clinical trials to confirm the clinical benefit of pralatrexate in patients with PTCL [&lt;ulink linkID="1045038" linkType="Reference"&gt;1045038&lt;/ulink&gt;], [&lt;ulink linkID="1045006" linkType="Reference"&gt;1045006&lt;/ulink&gt;]; the studies were to include phase I dose-escalating studies, a  phase III randomized study and two phase I trials to assess whether the drug poses the risk of altered drug levels due to organ impairment [&lt;ulink linkID="1642808" linkType="Reference"&gt;1642808&lt;/ulink&gt;]. Allos made  pralatrexate commercially available in October 2009,  and full-scale commercial launch commenced in January 2010 [&lt;ulink linkID="1047183" linkType="Reference"&gt;1047183&lt;/ulink&gt;], [&lt;ulink linkID="1078524" linkType="Reference"&gt;1078524&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Bladder cancer&lt;/subtitle&gt;In May 2010, pralatrexate was granted Orphan Drug status for advanced or metastatic transitional cell carcinoma of the urinary bladder  [&lt;ulink linkID="1100890" linkType="Reference"&gt;1100890&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other hematological malignancies&lt;/subtitle&gt;In November 2008, the drug was awarded Orphan Drug status for diffuse large B-cell lymphoma [&lt;ulink linkID="966212" linkType="Reference"&gt;966212&lt;/ulink&gt;]. The FDA awarded pralatrexate Orphan Drug status for follicular lymphoma  in December 2008 [&lt;ulink linkID="967840" linkType="Reference"&gt;967840&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Peripheral T-cell lymphoma&lt;/subtitle&gt;By January 2012, pralatrexate had been filed for approval in Switzerland for PTCL [&lt;ulink linkID="1256450" linkType="Reference"&gt;1256450&lt;/ulink&gt;]; by July 2017, approval had been granted in Switzerland  for PTCL [&lt;ulink linkID="1942971" linkType="Reference"&gt;1942971&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By December 2010, an MAA for pralatrexate had been filed and accepted for review under the centralized procedure in Europe for relapsed or refractory PTCL [&lt;ulink linkID="1157245" linkType="Reference"&gt;1157245&lt;/ulink&gt;]. However, in January 2012, the CHMP recommended against conditional approval of pralatrexate for the treatment of patients with PTCL whose disease had progressed after at least one prior systemic therapy [&lt;ulink linkID="1256450" linkType="Reference"&gt;1256450&lt;/ulink&gt;], [&lt;ulink linkID="1256468" linkType="Reference"&gt;1256468&lt;/ulink&gt;]. That same month, Allos  filed a request for re-examination of the negative opinion [&lt;ulink linkID="1258571" linkType="Reference"&gt;1258571&lt;/ulink&gt;]. In April 2012, the CHMP reaffirmed the negative opinion; at that time, the company planned to review the CHMP opinion and evaluate options for pursuing regulatory approval in Europe for this indication [&lt;ulink linkID="1282299" linkType="Reference"&gt;1282299&lt;/ulink&gt;], [&lt;ulink linkID="1282274" linkType="Reference"&gt;1282274&lt;/ulink&gt;]. In June 2012, the EC  adopted the CHMP's opinion and recommended against approval of the MAA; the decision was final and binding [&lt;ulink linkID="1398317" linkType="Reference"&gt;1398317&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2007, the EMA's COMP recommended that the drug be granted Orphan status for PTCL [&lt;ulink linkID="773572" linkType="Reference"&gt;773572&lt;/ulink&gt;]; Orphan status was granted the following month  [&lt;ulink linkID="785566" linkType="Reference"&gt;785566&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cutaneous T-cell lymphoma&lt;/subtitle&gt;In February 2010, the EMA's COMP recommended the drug be granted Orphan status for CTCL [&lt;ulink linkID="1074614" linkType="Reference"&gt;1074614&lt;/ulink&gt;]; the EC granted the drug Orphan status for CTCL in June 2010 [&lt;ulink linkID="1108807" linkType="Reference"&gt;1108807&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Bladder cancer&lt;/subtitle&gt;In March 2009, the EMA, following a positive recommendation from the COMP, granted pralatrexate Orphan status for advanced or metastatic relapsed  non-papillary transitional cell carcinoma of the urinary bladder [&lt;ulink linkID="992372" linkType="Reference"&gt;992372&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other hematological malignancies&lt;/subtitle&gt;In October 2010, the EC granted the drug Orphan status for Hodgkin lymphoma [&lt;ulink linkID="1139850" linkType="Reference"&gt;1139850&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;&lt;subtitle&gt;Peripheral T-cell lymphoma&lt;/subtitle&gt;In 2016, Mundipharma filed an application seeking approval in Japan, based on data from PDX-JP1 study and  the global phase II PROPEL study [&lt;ulink linkID="1942971" linkType="Reference"&gt;1942971&lt;/ulink&gt;]. In April 2017, the 2nd Committee of the New Drugs, Pharmaceutical Affairs and Food Sanitation Council of the Ministry of Health, Labour and Welfare recommended approval for the treatment of PTCL [&lt;ulink linkID="1923452" linkType="Reference"&gt;1923452&lt;/ulink&gt;]. In July 2017, the product (20 mg injection) was approved in Japan for the treatment of recurrent or refractory PTCL [&lt;ulink linkID="1942971" linkType="Reference"&gt;1942971&lt;/ulink&gt;]; in August 2017, launch occurred in Japan for that indication [&lt;ulink linkID="1962812" linkType="Reference"&gt;1962812&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2014, the Ministry of Health, Labour and Welfare in Japan granted pralatrexate Orphan designation for the treatment of PTCL [&lt;ulink linkID="1530537" linkType="Reference"&gt;1530537&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;&lt;subtitle&gt;Peripheral T-cell lymphoma&lt;/subtitle&gt;In January 2019, a filing for approval was submitted in China presumably for PTCL  [&lt;ulink linkID="2107483" linkType="Reference"&gt;2107483&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In January 2016, &lt;ulink linkID="22730" linkType="Company"&gt;Servier Canada&lt;/ulink&gt; gained exclusive rights to develop and commercialize the drug in Canada [&lt;ulink linkID="1726362" linkType="Reference"&gt;1726362&lt;/ulink&gt;]. By September 2018, a filing had been made with Health Canada for the treatment of relapsed or refractory PTCL [&lt;ulink linkID="2069900" linkType="Reference"&gt;2069900&lt;/ulink&gt;]. In October 2018, Health Canada granted a Notice of Compliance with conditions for pralatrexateÂ for the treatment of relapsed or refractory PTCL; the approval was supported by data from the phase II PROPEL trial    [&lt;ulink linkID="2089348" linkType="Reference"&gt;2089348&lt;/ulink&gt;], [&lt;ulink linkID="2110141" linkType="Reference"&gt;2110141&lt;/ulink&gt;]. By November 2018, the product was launched   [&lt;ulink linkID="2089348" linkType="Reference"&gt;2089348&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By September 2014, the drug was pending approval in Latin America for PTCL [&lt;ulink linkID="1598424" linkType="Reference"&gt;1598424&lt;/ulink&gt;]; however, no further development was reported. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;By September 2014, the drug was approved in Israel and was presumed to have been launched for PTCL [&lt;ulink linkID="1598424" linkType="Reference"&gt;1598424&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By September 2014, the drug was pending approval in Middle Eastern countries for PTCL [&lt;ulink linkID="1598424" linkType="Reference"&gt;1598424&lt;/ulink&gt;]; however, no further development was reported. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;&lt;subtitle&gt;T-cell lymphoma&lt;/subtitle&gt;By September 2014, the drug was pending approval in Asia for PTCL [&lt;ulink linkID="1598424" linkType="Reference"&gt;1598424&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2012, pralatrexate had been filed for approval in Australia for PTCL [&lt;ulink linkID="1256450" linkType="Reference"&gt;1256450&lt;/ulink&gt;]. In December 2012, the TGA rejected approval of the drug in Australia [&lt;ulink linkID="1753868" linkType="Reference"&gt;1753868&lt;/ulink&gt;]; by July 2017, approval had been granted in Australia for PTCL [&lt;ulink linkID="1942971" linkType="Reference"&gt;1942971&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2012, pralatrexate had been filed for approval in South Korea for PTCL [&lt;ulink linkID="1256450" linkType="Reference"&gt;1256450&lt;/ulink&gt;]. By February 2012, the drug had been granted orphan status in Korea [&lt;ulink linkID="1264872" linkType="Reference"&gt;1264872&lt;/ulink&gt;]. In July 2012, the drug was approved [&lt;ulink linkID="1753868" linkType="Reference"&gt;1753868&lt;/ulink&gt;]. The agent was made available in November 2012 [&lt;ulink linkID="1579590" linkType="Reference"&gt;1579590&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;&lt;subtitle&gt;Relapsed/refractory peripheral T-cell lymphoma&lt;/subtitle&gt;In September 2009, an accelerated approval was granted for PTCL. In connection with the approval, Allos agreed to conduct additional clinical trials to confirm the clinical benefit of pralatrexate in patients with PTCL [&lt;ulink linkID="1045038" linkType="Reference"&gt;1045038&lt;/ulink&gt;], [&lt;ulink linkID="1045006" linkType="Reference"&gt;1045006&lt;/ulink&gt;]; the studies were to include phase I dose-escalating studies, a  phase III randomized study and two phase I trials to assess whether the drug poses the risk of altered drug levels due to organ impairment [&lt;ulink linkID="1642808" linkType="Reference"&gt;1642808&lt;/ulink&gt;]. In February 2013, Spectrum stated that subject to post-approval requirements, two phase III, randomized trials were required to confirm pralatrexate's clinical benefit in T-cell lymphoma [&lt;ulink linkID="1398317" linkType="Reference"&gt;1398317&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Relapsed/refractory peripheral T-cell lymphoma&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In June 2015, a non-randomized, open-label, single-armed, phase III trial (CTR20150402) was planned to begin in Chinese patients  (n = 68) with relapsed or refractory PTCL [&lt;ulink linkID="1673732" linkType="Reference"&gt;1673732&lt;/ulink&gt;]. In September 2015, the study (&lt;ulink linkID="319944" linkType="Protocol"&gt;NCT03349333&lt;/ulink&gt;; FOT12-CN-301) began. The primary endpoint was ORR by international working group criteria, with time to response and PFS among secondary endpoints. At that time, the study was expected to complete in March 2019 [&lt;ulink linkID="2070155" linkType="Reference"&gt;2070155&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2017, patient recruitment for a multicenter phase II trial of pralatrexate plus &lt;ulink linkID="8023" linkType="Drug"&gt;romidepsin&lt;/ulink&gt; for PTLC was ongoing [&lt;ulink linkID="1938896" linkType="Reference"&gt;1938896&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2006, the company was planning an open-label, multicenter phase II trial in patients (n = 115) with relapsed or refractory PTCL [&lt;ulink linkID="666224" linkType="Reference"&gt;666224&lt;/ulink&gt;]. In August 2006, Allos agreed an SPA with the FDA for the phase II trial. The non-randomized trial would assess the safety and efficacy of a combination of vitamin B12, folic acid and pralatrexate (30 mg/m2) in 100 PTCL patients in the US, Canada and Europe. They were to receive 30 mg/m2 of pralatrexate once-weekly for 6 weeks in a 7 week cycle [&lt;ulink linkID="681536" linkType="Reference"&gt;681536&lt;/ulink&gt;], [&lt;ulink linkID="682369" linkType="Reference"&gt;682369&lt;/ulink&gt;]. Later in August 2006, enrollment began in the pivotal PROPEL study (&lt;ulink linkID="38905" linkType="Protocol"&gt;NCT00364923&lt;/ulink&gt;; PDX-008), with study completion expected in June 2010 [&lt;ulink linkID="1062839" linkType="Reference"&gt;1062839&lt;/ulink&gt;]. Enrollment would be completed in 18 to 24 months. The primary endpoint of the single-arm study would be objective response rate. Duration of response, progression-free survival (PFS) and overall survival were the secondary endpoints. Patients were treated with pralatrexate (30 mg/m2/week using iv push over 3 to 5 min) for 6 weeks in 7-week cycles, vitamin B12 (1 mg im) every 8-10 weeks and folic acid (1.0 to 1.25 mg po) daily [&lt;ulink linkID="686358" linkType="Reference"&gt;686358&lt;/ulink&gt;]. In January 2007, an independent data monitoring committee completed an interim analysis of safety data from the first ten patients to complete at least one cycle of treatment. No safety issues were raised and the committee recommended that Allos continue the trial as planned. Further interim analyses were expected after 35 and 65 patients had completed one treatment cycle [&lt;ulink linkID="755732" linkType="Reference"&gt;755732&lt;/ulink&gt;]. Interim data were reported in September 2007. Patient response exceeded the minimum level of four partial or complete responses from the first 35 patients required for continuation of the trial. At that time, the data monitoring committee completed an analysis of these patients and identified no safety concerns [&lt;ulink linkID="832743" linkType="Reference"&gt;832743&lt;/ulink&gt;]. In December 2007, an independent data monitoring committee recommended the continuation of the trial as per protocol following the completion of a 65-patient safety review of data from patients who had completed at least one cycle of pralatrexate treatment [&lt;ulink linkID="863628" linkType="Reference"&gt;863628&lt;/ulink&gt;]. In April 2008, enrollment was completed [&lt;ulink linkID="898874" linkType="Reference"&gt;898874&lt;/ulink&gt;]. In May 2008, further interim data were reported which showed that of 65 evaluable patients, a complete or partial response had been acheived by 29 or 45% of patients when assessed by the central independent oncology review or PROPEL investigators, respectively. The most commonly observed adverse events were mucositis and thrombocytopenia which were observed in 14 and 23% of patients, respectively [&lt;ulink linkID="906010" linkType="Reference"&gt;906010&lt;/ulink&gt;]. In December 2008, further interim data were reported at the 50th ASH meeting in San Francisco, CA. Results showed that 42 of 109 evaluable patients (39%) responded overall. 14 had a complete response, 4 had unconfirmed complete response, and 24 had a partial response. Mucosal inflammation and thrombocytopenia were the most common Grade 3-4 AEs [&lt;ulink linkID="968256" linkType="Reference"&gt;968256&lt;/ulink&gt;], [&lt;ulink linkID="969023" linkType="Reference"&gt;969023&lt;/ulink&gt;]. In February 2009, final data were reported and the trial's database had been locked. A total of 28% of patients achieved a response, which was the trial's primary endpoint. The median duration of response was 9.4 months. The most common adverse events were thrombocytopenia, mucosal inflammation, neutropenia and anemia, which were reported in 32, 21, 20 and 17% of patients [&lt;ulink linkID="981349" linkType="Reference"&gt;981349&lt;/ulink&gt;]. In June 2009, further data were presented at the 45th ASCO meeting in Orlando, FL. Of the 30 patients (28%) that had achieved a response, ten were complete responses and 20 were partial responses. Stable disease had been reported in a further 23 patients. Of the responders, median overall survival was 14.7 months and 57% of these patients survived &amp;gt; 12 months [&lt;ulink linkID="1031360" linkType="Reference"&gt;1031360&lt;/ulink&gt;]. In December 2009, further data were presented at the 51st ASH meeting in New Orleans, LA. Treatment with  pralatrexate achieved an overall response rate of 29%; 63% of patients responded within the first cycle of therapy. Responses were durable with a median duration of response of 10.1 months; median overall survival was 14.5 months. The data also suggested that there was no cumulative-dose toxicity [&lt;ulink linkID="1062493" linkType="Reference"&gt;1062493&lt;/ulink&gt;];  also presented at the meeting was an analysis showing that while  improvement in PFS had not been demonstrated, of patients who had progressed after receiving prior autologous SCT, 63% responded to pralatrexate with a response rate of 33%, compared to 29% observed in the overall PROPEL population [&lt;ulink linkID="1062694" linkType="Reference"&gt;1062694&lt;/ulink&gt;]. In June 2010, further data were presented at the 46th ASCO meeting in Chicago, IL. In a time-dependent covariate analyses of patients who responded to pralatrexate, a 44% reduction  in risk of death based on independent review of response, and a 56% reduction  based on investigator review of response, was observed. In the analyses, patients who responded to pralatrexate had a 31% reduction in risk of death  based on independent central review of response, and a 49% reduction in risk of death  based on investigator review of response [&lt;ulink linkID="1106031" linkType="Reference"&gt;1106031&lt;/ulink&gt;]. In December 2010, pooled data from three retrospective analyses of the PROPEL study were presented at the 52nd ASH meeting in Orlando, FL. Objective responses were observed in 40% of patients (n = 8) that had received &lt;ulink linkID="52416" linkType="Drug"&gt;ifosfamide&lt;/ulink&gt;, &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; and &lt;ulink linkID="3072" linkType="Drug"&gt;etoposide&lt;/ulink&gt; (ICE)-based therapies prior to pralatrexate treatment, suggesting that pralatrexate was effective in relapsed or refractory PTCL patients that had received prior ICE-based chemotherapy. Objective responses were observed in 47% of patients (n =7) treated with pralatrexate after disease progression following first-line CHOP therapy, indicating the efficacy of pralatrexate as a second-line treatment. In addition, the objective responses and PFS decreased in patients (n = 57) that had received three or more systemic therapies prior to PROPEL enrollment with each line of treatment prior to pralatrexate treatment. However, following pralatrexate therapy, objective responses and PFS increased relative to the immediate prior line of therapy [&lt;ulink linkID="1153954" linkType="Reference"&gt;1153954&lt;/ulink&gt;]. Further data from the PROPEL study were presented at the same meeting on pralatrexate for the treatment of relapsed/refractory transformed mycosis fungoides. Of the 12 patients observed, complete response (CR), unconfirmed CR and partial response were observed in 1, 2 and 5 patients, respectively, with an overall response rate of 58%. The drug was well tolerated with none of the patients discontinuing therapy due to adverse event (AEs); fatigue and thrombocytopenia were the grade 4 AEs observed [&lt;ulink linkID="1150331" linkType="Reference"&gt;1150331&lt;/ulink&gt;]. In January 2011, additional data from the PROPEL trial were reported. A total of 11% (n = 12) of patients receiving pralatrexate experienced a complete response or unconfirmed complete response. Of the 69 patients who had not responded to their most recent prior therapy, 25% (n = 17) responded to pralatrexate; of the 26 patients who had not responded to any prior therapy, 19% (n = 5) responded to pralatrexate. A medium overall survival of 14.5 months  was observed after a median follow-up period of 18 months, and PFS was 3.5 months. The most common Grade 3 to 4 adverse events were thrombocytopenia, mucositis, neutropenia, and anemia, which were reported in 32, 22, 22 and 18% of patients [&lt;ulink linkID="1162433" linkType="Reference"&gt;1162433&lt;/ulink&gt;], [&lt;ulink linkID="1162593" linkType="Reference"&gt;1162593&lt;/ulink&gt;]. In May 2011, similar data were published [&lt;ulink linkID="1190893" linkType="Reference"&gt;1190893&lt;/ulink&gt;]. In June 2011, data from  retrospective  analyses of the PROPEL study were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland. In pralatrexate-treated patients who received &amp;gt;/= 3 prior therapies, response rates increased from 30% to 40% relative to the previous line of therapy, and median PFS increased from 95 days to 134 days. In patients who received &amp;gt;/= 2 prior therapies, the corresponding increases relative to the previous line of therapy were from 29% to 40% and from 89.5 days to 119 days [&lt;ulink linkID="1200980" linkType="Reference"&gt;1200980&lt;/ulink&gt;]. In a subgroup of patients (n = 15) who had received CHOP as their first-line therapy, objective and complete responses were observed in 47% and 20% of patients, respectively,  as assessed by independent central review; the respective objective and complete responses as assessed by local investigators were 40% and 27%, respectively. PFS was  8.1 months according to the independent central review, and 7.4 months per the local investigator review [&lt;ulink linkID="1201105" linkType="Reference"&gt;1201105&lt;/ulink&gt;]. In June 2011, similar data were presented at the 16th EHA meeting in London, UK [&lt;ulink linkID="1198160" linkType="Reference"&gt;1198160&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I/II&lt;/subtitle&gt;In October 2013, Mundipharma initiated a clinical study in patients with relapsed or refractory PTCL in Japan [&lt;ulink linkID="1500545" linkType="Reference"&gt;1500545&lt;/ulink&gt;]. In September 2014, the phase II part of the phase I/II study was initiated. The study was expected to complete at the end of December 2017 [&lt;ulink linkID="1598600" linkType="Reference"&gt;1598600&lt;/ulink&gt;]; in August 2015, the phase I/II trial (&lt;ulink linkID="164020" linkType="Protocol"&gt;NCT02013362&lt;/ulink&gt;; PDX-JP1) was expected to complete in December 2013. The primary endpoint was objective response rate  in PTCL patients (expected n = 26) per independent central review committee at approximately 3 years [&lt;ulink linkID="1694731" linkType="Reference"&gt;1694731&lt;/ulink&gt;]. In September 2015, patient accrual was completed in the phase II part of the study [&lt;ulink linkID="1694561" linkType="Reference"&gt;1694561&lt;/ulink&gt;]. In August 2017, data from the trial were reported. The response rate was 45% (9/20) with 9 patients achieving a response in the first 7 weeks. At the time of data cut-off, the median rate of response period and median rate of overal suvival had not been achieved, at that time, the sustained response rate at day 344 was 57.1% [&lt;ulink linkID="1962812" linkType="Reference"&gt;1962812&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In June 2017, data were presented from a phase I trial at the 14th International Conference on Malignant Lymphoma meeting in Lugano, Switzerland. The trial evaluated pralatrexate plus romidepsin in patients with relapsed or refractory PTCL. A total of 52 patients were enrolled, with 29 enrolled patients evaluable for toxicity and 23 patients evaluable for response. The ORR in the total, non-PTCL and PTCL populations was 57, 33, and 71%, respectively. In the PTCL group, complete response, partial response and stable disease was achieved in 29 and 43% of patients and 1 patient had stable disease. The mean DOR in the PTCL population was 7.49 months, PFS was 5.9 months, and OS was 10.8 months in the heavily pretreated patient group [&lt;ulink linkID="1938896" linkType="Reference"&gt;1938896&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2013, Spectrum stated that subject to post-approval requirements, two phase I trials were to be conducted to assess whether pralatrexate posed a serious risk of altered drug levels resulting from organ impairment [&lt;ulink linkID="1398317" linkType="Reference"&gt;1398317&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;First-line peripheral T-cell lymphoma&lt;/subtitle&gt;In March 2017, a phase III trial of the combination of pralatrexate and CHOP compared to CHOP alone for the treatment of first-line PTCL was expected to be planned once the proper dose of pralatrexate in combination with CHOP would be determined. The trial's concept was designed to fulfill the FDA's postmarketing requirements under the accelerated approval [&lt;ulink linkID="1908613" linkType="Reference"&gt;1908613&lt;/ulink&gt;]; in March 2018, this was still the case [&lt;ulink linkID="2011720" linkType="Reference"&gt;2011720&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, an open-label, multicenter, two-part, dose-finding, dose-escalation, phase I trial (&lt;ulink linkID="244948" linkType="Protocol"&gt;NCT02594267&lt;/ulink&gt;; SPI-FOL-101) began in the US to assess the MTD of pralatrexate in combination with CHOP regimen in patients (expected n = 30) with newly diagnosed PTCL  [&lt;ulink linkID="2074710" linkType="Reference"&gt;2074710&lt;/ulink&gt;]. In March 2017, the phase I trial of the combination of pralatrexate and CHOP using a concept designed to fulfill  the FDA's postmarketing requirements under the accelerated approval was ongoing [&lt;ulink linkID="1908613" linkType="Reference"&gt;1908613&lt;/ulink&gt;]. In December 2017, data were presented at the 59th ASH Meeting in Atlanta, GA. MTD. At that time, 31 patients had been enrolled. In part 1 of the study, a pralatrexate dose of 30 mg/m(2) in combination with CHOP was selected for part 2. The combination therapy was generally well tolerated with median relative dose intensity (RDI) of 98%. In 29 patients evaluable for response, the overall   and complete response rates  were 90% and 66% respectively [&lt;ulink linkID="1991397" linkType="Reference"&gt;1991397&lt;/ulink&gt;]. In December 2017, further results were presented at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. Anemia (n = 6), fatigue (n = 4) and neutrophil count decrease (n = 5) were the most commonly reported (&amp;gt;/= 10%) grade &amp;gt;/= 3 AEs. Neutrophil count decrease (n = 4) was the only grade &amp;gt; 3 treatment-related AE (&amp;gt;/= 10%). A total of 13 patients experienced serious AEs (SAEs) and treatment-related SAEs included nausea, mucositis, dehydration, febrile neutropenia and anemia [&lt;ulink linkID="1988474" linkType="Reference"&gt;1988474&lt;/ulink&gt;]. In December 2017, the trial was expected to complete in December 2018 [&lt;ulink linkID="2074710" linkType="Reference"&gt;2074710&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2010, a phase III trial for previously undiagnosed patients with PTCL who had demonstrated a response to CHOP or a CHOP-like regimen was planned  [&lt;ulink linkID="1078434" linkType="Reference"&gt;1078434&lt;/ulink&gt;], [&lt;ulink linkID="1078524" linkType="Reference"&gt;1078524&lt;/ulink&gt;]. In March 2011, the company agreed an SPA for the trial with the FDA [&lt;ulink linkID="1172975" linkType="Reference"&gt;1172975&lt;/ulink&gt;], [&lt;ulink linkID="1172974" linkType="Reference"&gt;1172974&lt;/ulink&gt;]. In August 2011, the randomized, open-label, multicenter, global phase III trial (&lt;ulink linkID="80284" linkType="Protocol"&gt;NCT01420679&lt;/ulink&gt;; PDX-017) was initiated. The coprimary endpoints were progression-free survival and overall survival, and the company planned to enroll 549 patients. At that time, the first patient was enrolled and treated [&lt;ulink linkID="1215674" linkType="Reference"&gt;1215674&lt;/ulink&gt;], [&lt;ulink linkID="1349844" linkType="Reference"&gt;1349844&lt;/ulink&gt;]. By August 2014, the trial was terminated [&lt;ulink linkID="1349844" linkType="Reference"&gt;1349844&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2011, a phase II study (&lt;ulink linkID="76653" linkType="Protocol"&gt;NCT01336933&lt;/ulink&gt;) began to evaluate CEOP chemotherapy alternating with pralatrexate in the first-line treatment of peripheral T-cell non-Hodgkins lymphomas. The primary endpoint was complete response rate after 6 courses. The trial was expected to enroll 34 patients and complete in December 2015 [&lt;ulink linkID="1349849" linkType="Reference"&gt;1349849&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cutaneous T-cell lymphoma&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In March 2010, a phase III, multicenter, randomized study was planned, comparing  pralatrexate in combination with systemic bexarotene to systemic bexarotene treatment alone  in patients with CTCL  refractory to at least one prior systemic therapy.  Allos agreed with the FDA that results would be submitted to it by September  2015 [&lt;ulink linkID="1078524" linkType="Reference"&gt;1078524&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In December 2015, clinical data were presented from a phase I/II, open-label, dose-finding study, at the 57th ASH Annual Meeting and Exposition in Orlando, FL.  Patients (n = 34) were administered pralatrexate (15 mg/m2) + bexarotene (150 mg/m2) in cohort 1 and pralatrexate (15 mg/m2) + bexarotene (300 mg/m2) in cohort 2a. Dose reductions and omissions due to AEs were observed in 21 and 6% of patients, respectively related to pralatrexate and in 24 and 59% of patients, respectively related to bexarotene. With respect to mycosis fungoides (MF), transformed MF, sezary syndrome and anaplastic large cell lymphoma, overall response rate was observed in 12, 5, 2 and 1 patients, respectively complete response was 2, 1, 0 and 1 patients, respectively and partial response was 10, 4, 2 and 0 patients, respectively [&lt;ulink linkID="1718861" linkType="Reference"&gt;1718861&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2010, a phase I trial (&lt;ulink linkID="66932" linkType="Protocol"&gt;NCT01134341&lt;/ulink&gt;) to determine the MTD for pralatrexate plus &lt;ulink linkID="6600" linkType="Drug"&gt;bexarotene&lt;/ulink&gt; was planned for that year, and to be completed before the initiation of a phase III trial for CTCL. In March 2011, enrollment was ongoing; completion was scheduled for August 2013 [&lt;ulink linkID="1078524" linkType="Reference"&gt;1078524&lt;/ulink&gt;],  [&lt;ulink linkID="1078434" linkType="Reference"&gt;1078434&lt;/ulink&gt;], [&lt;ulink linkID="1105201" linkType="Reference"&gt;1105201&lt;/ulink&gt;], [&lt;ulink linkID="1108807" linkType="Reference"&gt;1108807&lt;/ulink&gt;], [&lt;ulink linkID="1198487" linkType="Reference"&gt;1198487&lt;/ulink&gt;]. In January 2012, interim data were presented at the fourth Annual T-cell Lymphoma Forum in San Francisco, CA. The MTD was determined to be pralatrexate 15 mg/m2 qw and bexarotene 150 mg/m2 daily. Of the ten patients evaluable for response (total treated = 14), 60% achieved a response, including one complete response and five partial responses; at the MTD, four of seven patients achieved a response, including one complete response and three partial responses. At that time, enrollment of the expanded cohort (total  n = 30) was ongoing [&lt;ulink linkID="1258558" linkType="Reference"&gt;1258558&lt;/ulink&gt;]. By February 2014, enrollment of an expected 42 patients was completed; at that time, the trial was expected to complete in December 2014 [&lt;ulink linkID="1105201" linkType="Reference"&gt;1105201&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2007, a multicenter, open-label phase I trial (&lt;ulink linkID="10757" linkType="Protocol"&gt;NCT00554827&lt;/ulink&gt;) was initiated. A total of 56 patients with relapsed or refractory disease would be treated with 30 mg/m2 of pralatrexate weekly for 2 or 3 weeks, plus vitamin B and folic acid. The primary objective would be to determine the optimal dose and to assess the drug's safety profile [&lt;ulink linkID="822207" linkType="Reference"&gt;822207&lt;/ulink&gt;]. In June 2008, interim data were presented at the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland. Of 14 evaluable patients, 5 achieved a complete response and 2  a partial response. The most common adverse event was mucositis but no grade 4 toxicities were reported [&lt;ulink linkID="914014" linkType="Reference"&gt;914014&lt;/ulink&gt;] In December 2008, further interim data were presented at the 50th ASH meeting in San Francisco, CA, on the PDX-010 phase I trial. By that time, 12 of the 22 evaluable patients achieved an overall response (55%), including partial response in 11 patients, and complete response in 1 patient. Treatment-related serious adverse events occurred in 3 patients and included stomatitis, chills, exfoliative dermatitis, hypoalbuminemia and tumor lysis syndrome. There was no greater than Grade 1 thrombocytopenia [&lt;ulink linkID="967135" linkType="Reference"&gt;967135&lt;/ulink&gt;], [&lt;ulink linkID="969025" linkType="Reference"&gt;969025&lt;/ulink&gt;]. In December 2009, data were presented at the 51st ASH meeting in New Orleans, LA, by which time 31 patients had been dosed. It was revealed that the optimum starting dose for pralatrexate treatment in CTCL patients was 15 mg/m2 administered weekly for 3 weeks out of a 4-week cycle. Responses were observed in 61% of patients treated at optimum dose compared to 39% in the overall study [&lt;ulink linkID="1063060" linkType="Reference"&gt;1063060&lt;/ulink&gt;]. In June 2010, data from 48 patients were presented at the 15th annual meeting of the European Hematology Association in Barcelona, Spain. Data showed that 45% of patients who received the optimal dose had a response; for patients who received greater or equal the optimal dose, a 53% response rate was observed including one complete response and 17 partial responses. Furthermore, in a subgroup analysis of patients who had failed key prior systemic therapies including patients who failed prior oral bexarotene, methotrexate failures, HDAC inhibitor failures and interferon failures, the responses to pralatrexate were 42%, 40%, 35% and 24%, respectively. At that time, enrollment in the study had been completed [&lt;ulink linkID="1107681" linkType="Reference"&gt;1107681&lt;/ulink&gt;]. In December 2010, data   were presented at the 52nd ASH meeting in Orlando, FL. Overall response rate was 45% in the 29 patients treated at the optimal starting dose and schedule. At this dose, the Kaplan-Meier estimate for duration of response was 73% at 6 months, and PFS ranged between 1 to 429 days; at that time, the median PFS had not been reached. Of the total 54 patients enrolled in the overall trial, objective responses were observed in 22 patients (41%) including three complete responses and 19 partial responses. A total of 41 patients were treated with the optimal dose or higher, and of these, responses were observed in 51% (n = 21). Responses were also observed in patients whose disease failed to respond to prior systemic therapies (oral bexarotene, methotrexate, HDAC inhibitors and interferon at 46, 46, 41 and 36%, respectfully) [&lt;ulink linkID="1153966" linkType="Reference"&gt;1153966&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;B-cell non-Hodgkins lymphomas&lt;/subtitle&gt;In September 2009, a phase II open-label, multicenter study (&lt;ulink linkID="61277" linkType="Protocol"&gt;NCT00998946&lt;/ulink&gt;) of pralatrexate in patients (n = 27) with relapsed or refractory B-cell NHL was initiated. Patients would be treated with  30 mg/m2 iv pralatrexate on days 1, 8 and 15 of a 4-week, with 1 mg im vitamin B12 and 1 mg po folic acid. The primary endpoint was objective response rate. Study completion was expected in June 2013  [&lt;ulink linkID="1078524" linkType="Reference"&gt;1078524&lt;/ulink&gt;], [&lt;ulink linkID="1105238" linkType="Reference"&gt;1105238&lt;/ulink&gt;]. In December  2012, the trial was no longer recruiting patients [&lt;ulink linkID="1174013" linkType="Reference"&gt;1174013&lt;/ulink&gt;]. In December 2014, the trial was completed [&lt;ulink linkID="1105238" linkType="Reference"&gt;1105238&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other hematological malignancies&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In December 2018, data from a single-arm, open-label, prospective multicenter phase II study which evaluated the management of grade 2 or higher oral mucositis (primary objective) with the use of leucovorin as adjunct to pralatrexate in treatment of patients with hematological malignancies including peripheral and cutaneous T-cell lymphomas, were presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA. Patients (n = 35) received iv pralatrexate (30 mg/m2, qw for 6 weeks in each cycle followed by a week of rest) and po leucovorin (25 mg tablets tid for 2 days after each pralatrexate dose).  Grade 2 oral mucositis was reported by two patients with duration of 13 and 7 days, respectively.   The rate of grade &amp;gt;/= 2 oral mucositis was 5.7%. Grade &amp;gt;/= 3 oral mucositis was not reported. A total of four patients reported grade 1 oral mucositis [&lt;ulink linkID="2098696" linkType="Reference"&gt;2098696&lt;/ulink&gt;], [&lt;ulink linkID="2100765" linkType="Reference"&gt;2100765&lt;/ulink&gt;], [&lt;ulink linkID="2100897" linkType="Reference"&gt;2100897&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By September 2011, a phase II trial of the drug in combination with pralatrexate plus &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt; for lymphoma had been initiated [&lt;ulink linkID="1223178" linkType="Reference"&gt;1223178&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In May 2007, enrollment began  in a phase I/IIa trial (&lt;ulink linkID="38900" linkType="Protocol"&gt;NCT00481871&lt;/ulink&gt;; PDX-009) in the US. During the 54-patient, dose-escalation phase I portion, patients with lymphoproliferative malignancies (diffuse large B- or T-cell lymphoma, mantle cell lymphoma, transformed large cell lymphomas, or Hodgkin's disease) would receive weekly pralatrexate, starting at a dose of 15 mg/m2, followed by gemcitabine the next day, starting at a dose of 400 mg/m2, for 3 or 4 weeks with concurrent vitamin B12 and folic acid supplements. The objectives of the phase I stage were an evaluation of the safety, tolerability, and pharmacokinetic profile of sequential pralatrexate and gemcitabine. The maximum tolerated dose would also be determined and would be used to treat 30 additional patients during the phase IIa portion of the study [&lt;ulink linkID="800746" linkType="Reference"&gt;800746&lt;/ulink&gt;], [&lt;ulink linkID="905037" linkType="Reference"&gt;905037&lt;/ulink&gt;]. In December 2007, pharmacokinetic phase I/IIa data were presented at the 49th ASH meeting in Atlanta, GA. The phase I portion treated patients with 30 to 255 of mg/m2 pralatrexate to set the MTD. In the phase II portion, patients were treated with 15 to 180 mg/m2 pralatrexate and the trial aimed to determine the effect of vitamin pretreatment. Data were available for 14 patients in the first portion and 33 in the second. The exposure best fit a linear three-compartment model. Vitamin pretreatment ameliorated toxicity [&lt;ulink linkID="858426" linkType="Reference"&gt;858426&lt;/ulink&gt;]. In December 2008, further results and modifications to the initial proposed dosing schedule were presented at the 50th ASH meeting in San Francisco, CA. The MTD for dosing on sequential days every 2 weeks was 10 mg/m2 of pralatrexate plus 300 mg/m2 of gemcitabine [&lt;ulink linkID="967137" linkType="Reference"&gt;967137&lt;/ulink&gt;], [&lt;ulink linkID="969025" linkType="Reference"&gt;969025&lt;/ulink&gt;]. In December 2009, further data were presented at the 51st ASH meeting in New Orleans, LA. Pralatrexate and gemcitabine had acceptable toxicity when administered every 2 weeks. Preliminary results showed   that pralatrexate and gemcitabine in lymphoid malignancies had a 24% overall response rate. A phase II expansion study was planned to evaluate both sequential and same-day dosing of pralatrexate every 2 weeks [&lt;ulink linkID="1062493" linkType="Reference"&gt;1062493&lt;/ulink&gt;]. Further data presented at the 51st ASH meeting in New Orleans, LA, showed that DLTs of grade 3/4 neutropenia and thrombocytopenia were observed in patients receiving pralatrexate at 15 mg/m2 and gemcitabine at 400 mg/m2. The MTD in subjects administered pralatrexate at 10 mg/m2 and gemcitabine at 300 mg/m2 was pralatrexate/gemcitabine at 10/400 mg/m2 when given on sequential days. The MTD in patients receiving same-day pralatrexate at 10 mg/m2 followed 1 h by gemcitabine at 300 mg/m2 was pralatrexate/gemcitabine at 15/600 mg/m2. Of 33 treated patients in the phase I portion, 8  had a partial response [&lt;ulink linkID="1058923" linkType="Reference"&gt;1058923&lt;/ulink&gt;]. By March 2011, the phase IIa component was closed to recruitment and  final  data were expected in 1H12   [&lt;ulink linkID="1096753" linkType="Reference"&gt;1096753&lt;/ulink&gt;], [&lt;ulink linkID="1140850" linkType="Reference"&gt;1140850&lt;/ulink&gt;], [&lt;ulink linkID="1174013" linkType="Reference"&gt;1174013&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2003, pralatrexate was  in phase I/II development for NHL [&lt;ulink linkID="495177" linkType="reference"&gt;495177&lt;/ulink&gt;]. In November 2005, enrollment in the phase I portion was to be completed in 4Q05 [&lt;ulink linkID="633489" linkType="Reference"&gt;633489&lt;/ulink&gt;]. By March 2006, the phase II portion for NHL had began [&lt;ulink linkID="653919" linkType="Reference"&gt;653919&lt;/ulink&gt;]. In August 2006, enrollment was ongoing [&lt;ulink linkID="682369" linkType="Reference"&gt;682369&lt;/ulink&gt;]. In November 2006, early-phase data were presented at the 18th EORTC-NCI-AACR meeting in Prague, Czech Republic. Based on data in lung cancer, doses of 135 mg/kg were given every other week in 16 patients with Hodgkins disease, aggressive B-cell lymphoma, mantle cell lymphoma, and PTCL.  A higher incidence of stomatitis was seen in patients with marked elevations in pretreatment homocysteine (Hcy)  and methylmalonic acid (MMA). Patients with elevated  Hcy and MMA who developed stomatitis with pralatrexate did not develop advanced stomatitis after  normalization of Hcy and MMA. With this established, the phase I trial was modified to a dose-escalation study starting at 30 mg/m2 weekly x 3 every 4 weeks, progressing to 30 mg/m2 x 6 every 7 weeks, and increasing by 15 mg/m2 on the 7-week schedule. The MTD was 30 mg/m2 x 6 every 7 weeks. At that time, 31 patients had been enrolled to the amended study, including three patients with Hodgkins disease, six with  diffuse large B-cell lymphoma, and 22 with various subtypes of TCL, giving a total of 42 patients with relapsed or refractory lymphoma in the amended and previous studies. Of these, eight complete responses had been recorded (all with T-cell lymphoma), and one partial remission. The longest duration of response was 9 months. Stomatitis was abrogated, and little hematological toxicity was observed. The study was ongoing to determine the objective response rate in patients with B- and T-cell lymphoma with a view to initiating a registration study in TCL [&lt;ulink linkID="742175" linkType="Reference"&gt;742175&lt;/ulink&gt;], [&lt;ulink linkID="741132" linkType="Reference"&gt;741132&lt;/ulink&gt;]. Similar data were reported at the 48th ASH meeting in Orlando, FL, in December 2006 [&lt;ulink linkID="770576" linkType="Reference"&gt;770576&lt;/ulink&gt;], and at the 19th  AACR-NCI-EORTC International Conference in San Francisco, CA, in October 2007 [&lt;ulink linkID="845166" linkType="Reference"&gt;845166&lt;/ulink&gt;]. In February 2007, data on pralatrexate were presented at the European Congress on Hematologic Malignancies in Athens, Greece. In a phase I/II trial, pralatrexate achieved an overall response rate of 50% in TCL patients [&lt;ulink linkID="770120" linkType="Reference"&gt;770120&lt;/ulink&gt;]. In November 2007, additional interim  data from the phase I/II trial were reported at the AHA Scientific Sessions in Orlando, FL.  A total of 14 of 26 evaluable TCL patients demonstrated a response to treatment, the duration of which, exceeded previously administered chemotherapy [&lt;ulink linkID="847541" linkType="Reference"&gt;847541&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In March 2010, a phase I study was planned to evaluate the pharmacokinetics of pralatrexate in relapsed or refractory B-cell (n = 6), T-cell (n = 6), and Hodgkin's lymphoma patients (n = 6) with mild to severe renal impairment.   Allos agreed with the FDA that results would be submitted to it by January  2013 [&lt;ulink linkID="1078524" linkType="Reference"&gt;1078524&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Breast cancer&lt;/subtitle&gt;By May 2010, a phase II, open-label, multicenter study in female patients with advanced or metastatic breast cancer (expected n = 30) had been initiated [&lt;ulink linkID="1096400" linkType="Reference"&gt;1096400&lt;/ulink&gt;]. In March 2011, enrollment was ongoing and interim analysis data were expected in 2H11 [&lt;ulink linkID="1174013" linkType="Reference"&gt;1174013&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Bladder cancer&lt;/subtitle&gt;In July 2008, Allos initiated a worldwide phase II trial (&lt;ulink linkID="38903" linkType="Protocol"&gt;NCT00722553&lt;/ulink&gt;) in patients with advanced or metastatic relapsed transitional cell carcinoma of the bladder. The open-label, single arm study planned to enroll 41 patients. Patients would be treated with iv pralatrexate on days 1 and 15 of a 28-day cycle at an initial dose of 190 mg/m2. The primary endpoint of the study was the objective response rate. The study was expected to complete in June 2013 [&lt;ulink linkID="926651" linkType="Reference"&gt;926651&lt;/ulink&gt;], [&lt;ulink linkID="1190909" linkType="Reference"&gt;1190909&lt;/ulink&gt;]. In March 2011, the study was ongoing and top-line data from the trial were expected in the second quarter of 2011 [&lt;ulink linkID="1119663" linkType="Reference"&gt;1119663&lt;/ulink&gt;]. In June 2012, data from 30 patients treated with pralatrexate (iv infusion/push) were presented at the 48th ASCO meeting in Chicago, IL. Overall, 1 patient showed confirmed partial response (PR), 4 other patients showed unconfirmed PR and 12 patients had stable disease (SD). The clinical benefit rate (complete response, PR or SD for at least 24 weeks) was 10%. The median PFS and OS  duration was 4 and 9.3 months, respectively [&lt;ulink linkID="1295791" linkType="Reference"&gt;1295791&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In January 2008, the company began enrollment in a phase IIb combination trial (&lt;ulink linkID="38904" linkType="Protocol"&gt;NCT00606502&lt;/ulink&gt;; PDX-012) for NSCLC. The global, randomized, multicenter study was to compare the efficacy of pralatrexate and  &lt;ulink linkID="11961" linkType="Drug"&gt;erlotinib&lt;/ulink&gt; in NSCLC patients who had failed treatment with at least one prior platinum-based chemotherapy regimen. Subjects were to receive concurrent vitamin therapy of B12 and folic acid plus 150 mg oral erlotinib daily or 230 mg/m2 pralatrexate on the first and fifteenth day of a 28-day cycle. The primary endpoint was overall survival. Secondary endpoints included response rate and PFS, and safety and tolerability of pralatrexate [&lt;ulink linkID="865389" linkType="Reference"&gt;865389&lt;/ulink&gt;]. In July 2009, enrollment was completed at 201 patients [&lt;ulink linkID="1023814" linkType="Reference"&gt;1023814&lt;/ulink&gt;]. Top-line data were reported in July 2010. Patients receiving pralatrexate demonstrated a 16% reduction in the risk of death, compared to erlotinib in the overall patient population (n = 201; hazard ratio = 0.84) and a 13% reduction in the risk of death in the primary efficacy analysis population (n = 166). The largest reductions in risk of death for pralatrexate were observed in patients with non-squamous cell carcinoma (n = 107; hazard ratio = 0.65) and light smokers (n = 37; hazard ratio = 0.63), demonstrating a 35  and 37% reduction in the risk of death, respectively [&lt;ulink linkID="1119450" linkType="Reference"&gt;1119450&lt;/ulink&gt;].  Additional data were presented at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy. At six months, 56% of patients treated with pralatrexate were alive, compared with 51% of patients treated with erlotinib; at one year, 28% of pralatrexate-treated patients were alive, compared with 18% of erlotinib-treated patients. The median overall survival was 6.7   and 7.0 months for patients who received pralatrexate and erlotinib, respectively. The safety profile of pralatrexate was consistent with that observed in previous studies [&lt;ulink linkID="1137890" linkType="Reference"&gt;1137890&lt;/ulink&gt;]. In December 2010, further data were presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology in Chicago, IL. Further data revealed that the OS hazard ratio, which favored pralatrexate was 0.73. Additionally, in patients with squamous cell carcinoma, a hazard ratio of 1.06 was observed for PFS. An exploratory analysis was conducted to assess the activity of pralatrexate relative to erlotinib in patients who remained on treatment at 30 days (n = 145), data of which showed a hazard ratio of 0.61, suggesting pralatrexate maintenance therapy may be important for efficacy. The safety profile of pralatrexate was consistent with that observed and reported in previous pralatrexate studies [&lt;ulink linkID="1155591" linkType="Reference"&gt;1155591&lt;/ulink&gt;]. In June 2011, further data were presented at the 47th ASCO meeting in Chicago, IL. In 107 patients with non-squamous histology, the trend of OS benefit with pralatrexate treatment was the greatest. In patients with squamous cell carcinoma, the activity of pralatrexate was found to comparable to that of erlotinib. The median progression-free survival duration was 3.4 months in the pralatrexate group, compared with 2.8 months in the erlotinib group.  In an analysis that evaluated patients who remained on treatment at 30 days, a trend towards OS benefit favoring pralatrexate treatment was observed [&lt;ulink linkID="1195633" linkType="Reference"&gt;1195633&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2001, phase II data were presented at the 37th ASCO meeting in San Francisco, CA, from a trial involving previously treated patients with NSCLC. Pralatrexate was administered to 24 patients at a dose of 150 mg/m2 iv every 2 weeks. Of 22 evaluable patients, 3 experienced partial responses of durations ranging from 3 to 13 months, and 10 had stable disease. Mucositis was the main dose limiting toxicity, seen in 32% of patients, while 9% had grade II transaminitis [&lt;ulink linkID="410511" linkType="Reference"&gt;410511&lt;/ulink&gt;]. In June 2003, researchers at Memorial Sloan-Kettering Cancer Center published phase II trial data in the June 2003 issue of Clinical Cancer Research, showing that pralatrexate may be an effective chemotherapy treatment for patients with NSCLC [&lt;ulink linkID="495265" linkType="reference"&gt;495265&lt;/ulink&gt;]. The study enrolled 39 patients with stage IIIB or IV NSCLC, who had either progressed after initial response or had stable disease to one previous chemotherapy regimen (92%), or had no previous chemotherapy (8%). Results showed a median survival time of 13.5 months, with 1 and 2-year survival rates of 56% and 36%, respectively. 10% of pralatrexate-treated patients had confirmed durable responses and 31% had stable disease. The response rate and symptomatic benefit were comparable to &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt;. The primary side effect of pralatrexate was stomatitis and no significant myelosuppression was observed [&lt;ulink linkID="495177" linkType="reference"&gt;495177&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In January 2005, Allos began a phase I study of pralatrexate with supplements of vitamin B12 and folic acid in patients with  NSCLC.Â The open-label, non-randomized dose escalation study would enroll cohorts of up to six patients with advanced NSCLC, who had been previously treated with chemotherapy. Cohorts would receive vitamin supplements and a 150 mg/m2 dose of pralatrexate, rising in 40 mg/m2 increments until dose limiting toxicities occur. The company planned to begin a phase II trial when it had determined the appropriate dosing level [&lt;ulink linkID="580825" linkType="Reference"&gt;580825&lt;/ulink&gt;]. In October 2007, data from this phase I trial were presented at the 19th AACR-NCI-EORTC International Conference in San Francisco, CA.  A total of 22 patients had been treated at the following doses: 150 (n = 1), 190 (n = 1), 230 (n= 1), 270 (n = 16) and 325 mg/m2 (n = 3). Folic acid and vitamin B12 were administered at 1 mg every 8 to 10 weeks, beginning &amp;gt; 7 days prior to chemotherapy. Grade 3 mucositis was reported in 5 out of the 16 patients at the 270 mg/m2 dose and in  2 out of the 3 patients receiving the 325 mg/m2 dose.  The addition of folic acid and vitamin B12 allowed higher doses of pralatrexate to be administered. Based on the dose-limiting toxicity, the maximum tolerated dose of pralatrexate was reported to be 270 mg/m2.  At this time, the recommended phase II dose was expected to be determined after reviewing  the final data  [&lt;ulink linkID="842140" linkType="Reference"&gt;842140&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2003, data were presented at the 15th AACR-NCI-EORTC meeting in Boston, MA. A phase I study was conducted to assess the safety of pralatrexate when combined with paclitaxel or docetaxel, iv every 2 weeks in patients with advanced cancer [&lt;ulink linkID="514403" linkType="reference"&gt;514403&lt;/ulink&gt;], [&lt;ulink linkID="513838" linkType="reference"&gt;513838&lt;/ulink&gt;]. By May 2005, a phase I study of pralatrexate in combination with a taxane was underway at the Memorial Sloan-Kettering Cancer Center, aimed at determining the optimal dose and toxicity profile of the drug when combined with a taxane [&lt;ulink linkID="599655" linkType="Reference"&gt;599655&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Mesothelioma&lt;/subtitle&gt;By June 2003, pralatrexate was  in  phase II trials for mesothelioma [&lt;ulink linkID="495177" linkType="reference"&gt;495177&lt;/ulink&gt;]. Data reported in April 2007 showed that the agent stabilized disease in patients when given pralatrexate [&lt;ulink linkID="891804" linkType="Reference"&gt;891804&lt;/ulink&gt;]. This indication was not listed on the company's January 2008 pipeline [&lt;ulink linkID="907518" linkType="Reference"&gt;907518&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;NCCN trials&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In November 2009, the National Comprehensive Cancer Network (NCCN), under a research grant from Allos, was planning  single-agent and combination studies in Burkitt's lymphoma, multiple myeloma, specific indolent lymphomas, ovarian cancer, head and neck cancer, prostate cancer, gastroesophageal cancer, and colorectal cancer [&lt;ulink linkID="1055980" linkType="Reference"&gt;1055980&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2010, a phase II, single-group, open-label efficacy study (&lt;ulink linkID="69032" linkType="Protocol"&gt;NCT01178944&lt;/ulink&gt;; NCI-2010-01583) of pralatrexate and &lt;ulink linkID="3792" linkType="Drug"&gt;oxaliplatin&lt;/ulink&gt; in patients (estimated n = 33) with unresectable or metastatic esophageal, stomach or gastroesophageal junction cancer was initiated in the US. The primary endpoint was overall response and the secondary endpoints included toxicity, progression-free survival and overall survival. The trial was expected to complete in May 2013. In August 2014, the trial was ongoing and expected to complete in September 2014 [&lt;ulink linkID="1198479" linkType="Reference"&gt;1198479&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2010, a phase II, non-randomized, single-group, open-label efficacy and safety study (&lt;ulink linkID="69298" linkType="Protocol"&gt;NCT01183065&lt;/ulink&gt;) of pralatrexate with vitamin B12 and folic acid supplementation in previously treated patients (estimated n = 14) with recurrent or metastatic HNSCC was initiated in the US. The primary endpoint was overall response rate, and the secondary endpoints included best overall response rate, progression-free survival and median overall survival. The trial was expected to complete in August 2012. In April 2014, the trial was completed [&lt;ulink linkID="1198487" linkType="Reference"&gt;1198487&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2010, a phase I/II,  non-randomized, single-group, open-label efficacy and safety study (&lt;ulink linkID="69569" linkType="Protocol"&gt;NCT01188876&lt;/ulink&gt;; 10-113) of &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; and pralatrexate in patients  (n = 50) with recurrent platinum-sensitive ovarian, fallopian or primary peritoneal cancer was initiated in the US. The primary endpoints were MTD and response rate, and the secondary endpoints included progression-free survival (PFS) and overall survival (OS). The trial was expected to complete in August 2013; the trial was completed in July 2017. In January 2018, results were reported. The maximum tolerated dose of pralatrexate in combination with carboplatin at one year was 105 mg/m2. In a best overall response analysis,   38% patients achieved  a partial response, 10% achieved progressive disease and 48% achieved  stable disease [&lt;ulink linkID="1198485" linkType="Reference"&gt;1198485&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2010, a phase II, non-randomized, single-group, open-label efficacy and safety study (&lt;ulink linkID="66737" linkType="Protocol"&gt;NCT01129206&lt;/ulink&gt;; NCI-2010-01225) of pralatrexate and &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; in patients (estimated n = 32) with advanced esophageal and gastroesophageal carcinoma who have failed prior platinum-based therapy was initiated in the US. The trial was expected to complete in December 2012. The primary endpoint was overall response and the secondary endpoints included progression-free survival and overall survival  [&lt;ulink linkID="1198465" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="1198478" linkType="Reference"&gt;1198478&lt;/ulink&gt;]. In June 2015, results were published. Stable disease (SD) was seen in two patients and four patients had disease progression per RECIST.  Patients (n = 2) had a partial response (PR) and patients (n = 2)  had SD when applying PERCIST criteria in four evaluable patients. Median PFS and median OS was 1.9 and   5.5  months, respectively [&lt;ulink linkID="1746489" linkType="Reference"&gt;1746489&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In August 2010, the NCCN initiated an open-label phase I study (&lt;ulink linkID="66055" linkType="Protocol"&gt;NCT01114282&lt;/ulink&gt;; SU-04282010-5783; 18556; HEMMYL0014) of pralatrexate in combination with &lt;ulink linkID="15954" linkType="Drug"&gt;bortezomib&lt;/ulink&gt; in 28 patients with previously treated multiple myeloma in the US.  The trial was expected to complete in December 2012. In August 2014, the trial was ongoing and expected to complete in June 2015  [&lt;ulink linkID="1110266" linkType="Reference"&gt;1110266&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2010, a phase I, open-label, single-group  safety study (&lt;ulink linkID="70537" linkType="Protocol"&gt;NCT01206465&lt;/ulink&gt;; NCI-2010-02014) of sequential pralatrexate followed by 5-fluorouracil (q2w) in patients (estimated n = 18) with solid tumors was initiated in the US.  The primary endpoints were DLT and safety and secondary endpoints included clinical response, time to disease progression and pharmacokinetics. The trial was expected to complete in September 2013. In August 2011, the trial was ongoing [&lt;ulink linkID="1198465" linkType="Reference"&gt;1198465&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous studies&lt;/subtitle&gt;In December 2015, clinical data were presented from an open-label, non-randomized, phase I trial, at the 57th ASH Annual Meeting and Exposition in Orlando, FL. Patients (n = 29) with normal (cohort A), mild (cohort B) and moderate (cohort C) renal function received pralatrexate 30 mg/m2 for 6 weeks and with severe (n = D) renal function received pralatrexate 20 mg/m2. Cmax (microg/ml), Tmax (min), AUC infinity (microg.ml/min), renal clrearance (ml/min), Vd (l) and t1/2 (h) was 2.37, 9, 99.8, 293, 123 and 21.9, respectively in cohort A, 2.98, 8, 126, 245, 89 and 22.9, respectively in cohort B, 2.81, 5, 118, 302, 76 and 23.6, respectively in cohort C and 1.57, 4, 87.8, 173, 170 and 26.5, respectively in cohort D for pralatrexate-10a and 2.94, 9, 164.9, 171, 55 and 16.1, respectively in cohort A, 3.66, 8, 238.5, 122, 35 and 17.9, respectively in cohort B, 3.23, 5, 214.8, 154, 37 and 11.7, respectively in cohort B, 1.92, 4, 179.1, 88, 78 and 21.8, respectively in cohort D for pralatrexate-10b diastereomers [&lt;ulink linkID="1718465" linkType="Reference"&gt;1718465&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2011, a phase I, mass balance  study to evaluate the excretion and metabolic profile of pralatrexate was ongoing [&lt;ulink linkID="1174013" linkType="Reference"&gt;1174013&lt;/ulink&gt;]. In April 2013, data were presented at the 104th AACR Annual Meeting in Washington, DC. Patients (n = 4) received a mixture of [14C]-pralatrexate (0.5 mg) and non-radiolabeled pralatrexate (224.5 mg) as a 3 to 5 min iv injection.  The percentage of [14C]-pralatrexate ranged from 22.40 to 44.80% in urine, 1.88 to 77.22% in feces and 3.03 to 0.91% in expired air. The AUC, plasma clearance, volume of distribution (V) 1, V2 and V3 of [14C]-pralatrexate ranged from 12.26 to 23.05 microCurie.h/l, 2.16 to 8.15 l/h, 3.68 to 27.20 l, 7.40 to 13.23 l and 403 to 1458 l, respectively [&lt;ulink linkID="1401633" linkType="Reference"&gt;1401633&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2003,  data were presented at the 15th AACR-NCI-EORTC meeting in Boston, MA. Pralatrexate administered in combination with docetaxel and folate or vitamin B12 supplements was active, well tolerated, and was thought to merit phase II testing for patients with metastatic NSCLC and other types of cancer where pralatrexate demonstrates single-agent activity [&lt;ulink linkID="514403" linkType="reference"&gt;514403&lt;/ulink&gt;], [&lt;ulink linkID="513838" linkType="reference"&gt;513838&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;At the 1998 ASCO meeting, interim results from a phase I study in patients with advanced solid tumors, using an accelerated dose escalation schedule, were reported. Seven dose levels were planned, and the intention was to enter one patient at each dose level, with three or six patients studied if toxicity was seen. Weekly administration at 30 mg/m2 iv x2 was planned, and subsequently 15, 30, 40, 50, 60 and 70 mg/m2 iv every two weeks x2. On the weekly schedule, side effects of stomatitis, photosensitivity/rash, leukopenia, anemia, epistaxis and nausea were noted. Adverse events of nausea, mucositis and epistaxis were observed on the two-weekly schedule, but these were not dose-related. Pralatrexate demonstrated a mild toxicity profile. The maximum tolerated dose was not reached and, at the time, dose escalation was continuing at one patient/dose level until toxicity was feasible [&lt;ulink linkID="288851" linkType="reference"&gt;288851&lt;/ulink&gt;], [&lt;ulink linkID="866857" linkType="Reference"&gt;866857&lt;/ulink&gt;]. Phase I data were presented at the 1999 ASCO meeting. The maximum tolerated dose had not been reached, with levels varying from 30 to 120 mg/m2. Data showed that pralatrexate was well tolerated and instances of stable disease had been observed [&lt;ulink linkID="327323" linkType="reference"&gt;327323&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In December 2013, preclinical data were presented at the 55th ASH Meeting in New Orleans, LA. In MM.1S myeloma cell line, pralatrexate treatment resulted in cell cycle disruption.  In MM.1S-Luc NOG mice, pralatrexate (60 mg/kg, biw) exhibited anti-myeloma activity [&lt;ulink linkID="1504344" linkType="Reference"&gt;1504344&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2013, preclinical data were presented at the 31st Annual JPMorgan Healthcare Conference in San Francisco, CA. Studies were ongoing for pralatrexate in combination with &lt;ulink linkID="39159" linkType="Drug"&gt;belinostat&lt;/ulink&gt; [&lt;ulink linkID="1355959" linkType="Reference"&gt;1355959&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, preclinical data were presented at the 102nd AACR meeting in Orlando, FL. In vitro,  pralatrexate demonstrated cytotoxicity in various human cancer cell lines with IC50 values in the range of 0.01 to &amp;gt;/= 350 microM. Synergistic antitumor activity was seen when  head and neck cancer HEP2 cells and prostate cancer DU145, PC3 and LNCAP cells were treated with pralatrexate followed by EGFR inhibitors (erlotinib, &lt;ulink linkID="11603" linkType="Drug"&gt;gefitinib&lt;/ulink&gt; and &lt;ulink linkID="33591" linkType="Drug"&gt;lapatinib&lt;/ulink&gt;) [&lt;ulink linkID="1175213" linkType="Reference"&gt;1175213&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2009, preclinical data were presented at the 100th AACR meeting in Denver, CO. Pralatrexate was shown to be 3- to 19-fold more potent than methotrexate against a panel of cancer cell lines [&lt;ulink linkID="993553" linkType="Reference"&gt;993553&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, preclinical data were presented at the 19th AACR-NCI-EORTC International Conference in San Francisco, CA. The in vivo activity of pralatrexate  was evaluated in comparison with methotrexate and &lt;ulink linkID="3536" linkType="Compound"&gt;pemetrexed&lt;/ulink&gt;. In two human NSCLC xenograft mouse models (MV522 and H460), pralatrexate (1 or 2 mg/kg ip) produced greater tumor regression compared with methotrexate (1 or 2 mg/kg ip) or &lt;ulink linkID="3536" linkType="Compound"&gt;pemetrexed&lt;/ulink&gt; (150 mg/kg ip) [&lt;ulink linkID="842115" linkType="Reference"&gt;842115&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2006, preclinical data of pralatrexate in combination with gemcitabine compared to methotrexate with cytarabine were published. In in vivo and in vitro models of lymphoma, the pralatrexate combination was shown to be superior to the methotrexate combination, resulting in more potent  apoptosis induction and significant reduction in tumor burden  in mice. Schedule-dependent interactions were observed with a sequence of pralatrexate followed by gemcitabine shown to be 5-fold more effective than simultaneous administration of the drugs [&lt;ulink linkID="650221" linkType="Reference"&gt;650221&lt;/ulink&gt;], [&lt;ulink linkID="650477" linkType="Reference"&gt;650477&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2001, data were presented at the 43rd ASH meeting in Orlando, FL. Pralatrexate demonstrated tenfold greater cytotoxicity than methotrexate against a panel of NHL cell lines, with an IC50 value of 3 to 5 nM. In NOD/SCID mouse models of NHL, 60 mg/kg ip pralatrexate caused significant tumor regression [&lt;ulink linkID="432787" linkType="reference"&gt;432787&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In studies using human cancer xenografts, pralatrexate demonstrated superiority over other antifolates and had produced significantly more cures. Preclinical toxicology was similar to that of methotrexate, with less toxicity [&lt;ulink linkID="288851" linkType="reference"&gt;288851&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In November 2009, the NCCN was awarded a research grant from Allos to assess the role of pralatrexate in the treatment of solid tumors and hematologic malignancies [&lt;ulink linkID="1055980" linkType="Reference"&gt;1055980&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Julian R Molina, Department of Oncology, &lt;ulink linkType="Company" linkID="21111"&gt;Mayo Clinic College of Medicine&lt;/ulink&gt;, Rochester, USA&lt;/para&gt;&lt;para&gt;Submission date: 27 March 2008&lt;br/&gt;Publication date: 16 July 2008&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Abstract&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="17990"&gt;Pralatrexate&lt;/ulink&gt;, a 10-deazaaminopterin derivative, is being developed by &lt;ulink linkType="Company" linkID="23253"&gt;Allos Therapeutics Inc&lt;/ulink&gt; for the potential treatment of malignancies. The folate analog inhibits dihydrofolate reductase and was developed to overcome the limitations of the folate analog methotrexate. Compared with methotrexate in preclinical studies, &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; demonstrated superior intracellular transport via the reduced folate carrier, and increased accumulation within cells by enhanced polyglutamylation. Preclinical studies in vitro and in models of B-cell lymphomas, T-cell lymphomas and NSCLC indicated that &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; exhibited antitumor activity that was superior to the activity of other antifolates. In phase I clinical trials, the DLT for &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; was mucositis, which could be abrogated with folic acid and vitamin B12 supplementation. The administration of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; to patients with T-cell lymphomas and NSCLC resulted in significant tumor remissions. At the time of publication, &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; was in phase II clinical trials for the treatment of peripheral T-cell lymphoma, a phase I/II trial in combination with &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; for the treatment of non-Hodgkin's lymphoma, and a phase IIb trial in comparison with &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt; in patients with NSCLC. Because of the limited therapies available for peripheral T-cell lymphoma, &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; could have a secure niche for the treatment of this indication, if ongoing clinical trials and future phase III trials confirm the efficacy of the drug. In contrast, for &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; to be incorporated into the accepted treatment options for NSCLC, the drug will need to prove clear superiority to established agents. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;The inhibition of the folate enzymes dihydrofolate reductase (DHFR) and thymidylate synthase is a well-validated method of cancer treatment. Several launched antifolate anticancer agents, including methotrexate, &lt;ulink linkType="Drug" linkID="3536"&gt;pemetrexed&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3323"&gt;raltitrexed&lt;/ulink&gt;, act via an inhibition of these enzymes [&lt;ulink linkType="Reference" linkID="905293"&gt;905293&lt;/ulink&gt;]. DHFR reduces dihydrofolic acid to tetrahydrofolic acid - a compound that is required by dividing cells for the synthesis of thymine. Reduced thymine levels following DHFR inhibition prevent cell division in rapidly dividing cancer cells [&lt;ulink linkType="Reference" linkID="905293"&gt;905293&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905294"&gt;905294&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The cellular uptake of antifolate agents is mediated by reduced folate carrier 1 (RFC1), and the antifolates are retained intracellularly via polyglutamylation catalyzed by folylpoly-gamma-glutamate synthetase (FPGS) [&lt;ulink linkType="Reference" linkID="905295"&gt;905295&lt;/ulink&gt;]. Methotrexate, which uses this pathway, has been used to treat various cancers, including bladder cancer and non-Hodgkin's lymphomas (NHLs; eg, diffuse large B-cell lymphoma [DLBCL], Burkitt's lymphoma and primary CNS lymphomas) [&lt;ulink linkType="Reference" linkID="905296"&gt;905296&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905297"&gt;905297&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905299"&gt;905299&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905302"&gt;905302&lt;/ulink&gt;]. However, methotrexate is associated with myelotoxicity [&lt;ulink linkType="Reference" linkID="905303"&gt;905303&lt;/ulink&gt;], and resistance to this antifolate and similar agents has evolved [&lt;ulink linkType="Reference" linkID="905304"&gt;905304&lt;/ulink&gt;], leading to the need to develop new cytotoxic agents. &lt;/para&gt;&lt;para&gt;Tumor cell mutations that cause an inhibition of the polyglutamylation cellular retention mechanism are a common method of tumor resistance to methotrexate [&lt;ulink linkType="Reference" linkID="905295"&gt;905295&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905304"&gt;905304&lt;/ulink&gt;]. Thus, compounds with a greater affinity for RFC1 (to improve membrane transport) and FPGS (to enhance polyglutamylation and, therefore, intracellular retention) than methotrexate have been designed to enhance antitumor activity [&lt;ulink linkType="Reference" linkID="50869"&gt;50869&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="866859"&gt;866859&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905868"&gt;905868&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="17990"&gt;Pralatrexate&lt;/ulink&gt;, a small-molecule DHFR inhibitor, is being developed by &lt;ulink linkType="Company" linkID="23253"&gt;Allos Therapeutics Inc&lt;/ulink&gt;, under license from the &lt;ulink linkType="Company" linkID="22122"&gt;Memorial Sloan-Kettering Cancer Center&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="22122"&gt;MSKCC&lt;/ulink&gt;) and &lt;ulink linkType="Company" linkID="20234"&gt;SRI International&lt;/ulink&gt;, for the potential treatment of malignancies [&lt;ulink linkType="Reference" linkID="475651"&gt;475651&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="475752"&gt;475752&lt;/ulink&gt;]. Phase I and II clinical trials with the drug as monotherapy have been completed in patients with NSCLC [&lt;ulink linkType="Reference" linkID="495265"&gt;495265&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="842140"&gt;842140&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="866857"&gt;866857&lt;/ulink&gt;], mesothelioma [&lt;ulink linkType="Reference" linkID="891804"&gt;891804&lt;/ulink&gt;] and hematological malignancies [&lt;ulink linkType="Reference" linkID="866865"&gt;866865&lt;/ulink&gt;]; and have been completed in patients with solid tumors (mainly NSCLC) in combination with probenecid [&lt;ulink linkType="Reference" linkID="866863"&gt;866863&lt;/ulink&gt;], &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="806863"&gt;806863&lt;/ulink&gt;]. At the time of publication, &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; was in phase II clinical trials for the treatment of peripheral T-cell lymphoma [&lt;ulink linkType="Reference" linkID="822207"&gt;822207&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905026"&gt;905026&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905167"&gt;905167&lt;/ulink&gt;], in a phase I/II trial in combination with &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; for the treatment of NHL [&lt;ulink linkType="Reference" linkID="800746"&gt;800746&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905037"&gt;905037&lt;/ulink&gt;] and in a phase IIb trial in comparison with &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt; in patients with NSCLC [&lt;ulink linkType="Reference" linkID="865389"&gt;865389&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905015"&gt;905015&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;To improve the antitumor activities of methotrexate (4-amino-N10-methylpteroylglutamic acid), 4-amino folate analogs were evaluated. Compared with methotrexate, the 10-alkyl (methyl, ethyl and dimethyl) analogs of 10-deazaaminopterin were determined to be more potent inhibitors of DHFR and exhibit greater efficiency for FPGS polyglutamylation; these effects were reflected by superior antitumor activities compared with methotrexate [&lt;ulink linkType="Reference" linkID="50869"&gt;50869&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="50870"&gt;50870&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905867"&gt;905867&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905868"&gt;905868&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="3012"&gt;Edatrexate&lt;/ulink&gt;, a 10-ethyl analog of 10-deazaaminopterin, was initially selected for clinical development because the compound was the most effective analog and was rapidly polyglutamylated [&lt;ulink linkType="Reference" linkID="50869"&gt;50869&lt;/ulink&gt;]. By 1998, &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt; had demonstrated significant response rates in phase III clinical trials in patients with cancer [&lt;ulink linkType="Reference" linkID="264811"&gt;264811&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="470116"&gt;470116&lt;/ulink&gt;]; however, studies with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;, the 10-propargyl analog, demonstrated superior cytotoxic and antitumor activities with excellent biochemical and cellular pharmacokinetic properties [&lt;ulink linkType="Reference" linkID="903080"&gt;903080&lt;/ulink&gt;], which presumably led to the precedence for the development of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; over &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="17990"&gt;Pralatrexate&lt;/ulink&gt; was synthesized by alkylation of the anion of dimethyl homoterephthalate with propargyl bromide, promoted by potassium hydride in dimethylformamide to afford the alpha-propargyl diester in 83% yield. Further alkylation of the potassium salt of alpha-propargyl diester with 2,4-diamino-6-(bromomethyl)pteridine yielded the dimethyl ester of 2,4-diamino-4-deoxy-10-propargyl-10-deazapteroic acid in 90% yield; the dimethyl ester was saponified with sodium hydroxide in 2-methoxyethanol to yield the diacid. A solution of the diacid in dimethylsulfoxide at 120degC resulted in rapid decarboxylation, and subsequent coupling of the diamino pteroic acid intermediate with diethyl l-glutamate using a mixed anhydride method produced the diethyl ester of 10-propargyl-10-deazaaminopterin; this ester was hydrolyzed with sodium hydroxide in 2-methoxyethanol to yield &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; in 95% purity [&lt;ulink linkType="Reference" linkID="866859"&gt;866859&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical development&lt;/subtitle&gt;&lt;subtitle&gt;Efficacy as a single agent and mechanism of action&lt;/subtitle&gt;In vitro&lt;br/&gt;&lt;ulink linkType="Drug" linkID="17990"&gt;Pralatrexate&lt;/ulink&gt; was approximately 3-fold less potent in inhibiting DHFR derived from murine leukemia L1210 cells (Ki = 18.2 pM) than methotrexate (Ki = 5.75 pM) and &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt; (Ki = 4.8 pM). However, in these cells, &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; inhibited growth with an IC50 value of 2.00 nM, compared with 9.50 and 1.44 nM for methotrexate and &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt;, respectively. A competitive binding assay for the transport protein (presumed to be RFC1) demonstrated that &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; had a transport advantage over methotrexate and &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt; (Ki = 0.45, 4.20 and 0.83 pM for &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;, methotrexate and &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt;, respectively) [&lt;ulink linkType="Reference" linkID="866859"&gt;866859&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Similarly, &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; was 2- to 3-fold less effective in inhibiting DHFR derived from human leukemia CCRF-CEM cells (Ki = 13.4 pM) than methotrexate (Ki = 5.4 pM) and &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt; (Ki = 5.8 pM). However, the drug was more effectively transported into cells by RFC1 compared with methotrexate and &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt; (the first-order rate constant of capacity for influx/saturability for influx [Vmax/Km] of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; was 12-fold greater than for methotrexate and 3-fold greater than for &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt;). &lt;ulink linkType="Drug" linkID="17990"&gt;Pralatrexate&lt;/ulink&gt; was also a more effective substrate for FPGS (the first-order rate constant of Vmax/Km of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; was 10-fold greater than for methotrexate and 2-fold greater than for &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt;), indicating improved polyglutamylation [&lt;ulink linkType="Reference" linkID="903080"&gt;903080&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The differential activity and potential mechanism of action of radiolabeled &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (5 microM), methotrexate (5 microM) and &lt;ulink linkType="Drug" linkID="3536"&gt;pemetrexed&lt;/ulink&gt; (20 microM) were assessed in human NSCLC MV522 and H460 cells. The expression of RFC1 in these cells was below the limit of detection (using RT-PCR). The total uptake of radiolabeled drug was similar at 15 and 60 min for methotrexate, decreased over time for &lt;ulink linkType="Drug" linkID="3536"&gt;pemetrexed&lt;/ulink&gt;, and increased over time for &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;. A smaller quantity of radiolabeled methotrexate entered cells compared with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3536"&gt;pemetrexed&lt;/ulink&gt;. Polyglutamylated &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; appeared in lysates from &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;-treated cells in a time-dependent manner, whereas less polyglutamylation was observed in methotrexate- and &lt;ulink linkType="Drug" linkID="3536"&gt;pemetrexed&lt;/ulink&gt;-treated cells, suggesting an improved polyglutamylation of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="842115"&gt;842115&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Cytotoxicity studies following a 3-h pulse exposure of the drugs in cultures of CCRF-CEM, human breast cancer MDA-468, SK-BR-3 and ZR-75-1 cells, and human NSCLC SK-LC8 and SK-LC16 cells demonstrated that &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; was 15- to 40-fold more potent (IC50 = 0.04 to 0.42 microM) than methotrexate (IC50 = 1.2 to 10.3 microM), and 3- to 4-fold more potent than &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt; (IC50 = 0.14 to 1.24 microM) [&lt;ulink linkType="Reference" linkID="903080"&gt;903080&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In human mesothelioma VAMT-1 and JMN cells, &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; was 25- to 30-fold more potent (IC50 = 23 to 27 nM) than methotrexate (IC50 = 634 to 683 nM) and 3-fold more potent than &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt; (IC50 = 77 to 98 nM) [&lt;ulink linkType="Reference" linkID="891822"&gt;891822&lt;/ulink&gt;]. The efficacy of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; was also compared with methotrexate in the human lymphoma cell lines RL (transformed follicular), HT (DLBCL), Hs602 (B-cell lymphoma), Hs445 (Hodgkin's disease), Raji (Burkitt's lymphoma) and SKI-DLBCL-1 (de novo DLBCL). &lt;ulink linkType="Drug" linkID="17990"&gt;Pralatrexate&lt;/ulink&gt; was determined to be 10-fold more cytotoxic (IC50 = 3 to 5 nM) than methotrexate (IC50 = 30 to 50 nM) [&lt;ulink linkType="Reference" linkID="432787"&gt;432787&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="866853"&gt;866853&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In vivo&lt;br/&gt;Nude mice xenografted with human mammary cancer MX1, lung cancer LX1 and squamous cell lung cancer A549 were injected with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (3 mg/kg), methotrexate (1.5 mg/kg) or &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt; (2 mg/kg) once daily for 5 days. None of the mice were observed to experience complete regression with methotrexate. In contrast, &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt; caused complete regression in 36 and 30% of MX1 and LX1 xenografted animals, respectively, but caused no regression in A549 xenografts. &lt;ulink linkType="Drug" linkID="17990"&gt;Pralatrexate&lt;/ulink&gt; was determined to have superior effects: complete regression was observed in 76, 85 and 30% of MX1, LX1 and A549 xenografted mice, respectively [&lt;ulink linkType="Reference" linkID="903080"&gt;903080&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;NOC/SCID mice xenografted with HT, RL and SKI-DLBCL-1 tumor cells were treated intraperitoneally with a saline control, &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (60 mg/kg) or methotrexate (40 mg/kg) twice weekly for three or four doses [&lt;ulink linkType="Reference" linkID="432787"&gt;432787&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="866853"&gt;866853&lt;/ulink&gt;]. Complete lymphoma regression was observed in 89, 56 and 30% of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;-treated HT, RL and SKI-DLBCL-1 xenografted mice, respectively, whereas complete regressions were not observed following treatment with methotrexate. The average tumor diameter in HT xenografts was 11.2 mm in controls, 0.5 mm after treatment with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;, and 8.7 mm following treatment with methotrexate; in RL xenografts, the respective average tumor diameters were 12.5, 2.7 and 10.9 mm, and were 12.0, 3.5 and 9.5 mm in SKI-DLBCL-1 xenografts. The sensitivity of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; in HT cells was associated with a 2- to 3-fold higher expression of the RFC1 gene compared with expression in RL or SKI-DLBCL-1 cells [&lt;ulink linkType="Reference" linkID="866853"&gt;866853&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Efficacy in combination&lt;/subtitle&gt;The combination of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (2 nM) and &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (20 nM) was assessed in the human NHL cell lines SKI-DLBCL-1, HI, DOHH2 and RL, all of which were exposed to one drug for 24 h followed by the same drug or the other drug for a further 24 h, or to the combination for 24 h. Synergistic cytotoxicities were observed in all cell lines, and the strongest synergistic effect was noted when &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; was administered prior to &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;: compared with the cytotoxicity of both drugs administered as monotherapy, cytotoxicity from the additive effects of the drugs was increased by 10.9, 13.5, 25.5 and 28.4% in SKI-DLBCL-1, HT, DOHH2 and RL cells, respectively. The same combinations of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; were tested in mice xenografted with SKI-DLBCL-1 cells; mice received four intraperitoneal doses of saline control, &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (60 mg/kg), &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (60 mg/kg) or the combination of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (administered concomitantly at doses of 30 mg/kg) twice weekly. Rapid disease progression was observed in controls, leading to euthanasia of the animals at 22 days after the initiation of treatment. Following monotherapy, tumor volumes initially decreased, but then increased to 739.0 and 317.7% of the initial tumor volume by day 44 for &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;, respectively. In contrast, tumor reductions of 63.1% of the initial tumor volume were observed by day 44 in mice receiving the drugs in combination; three complete regressions, one partial regression and one case of disease progression were observed (out of five animals) [&lt;ulink linkType="Reference" linkID="866851"&gt;866851&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="866854"&gt;866854&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Combinations of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; were further compared with the combination of methotrexate and cytosine arabinoside (which had demonstrated synergistic cytotoxic effects in leukemia cell lines [&lt;ulink linkType="Reference" linkID="905313"&gt;905313&lt;/ulink&gt;]), &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and cytosine arabinoside, and methotrexate and &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;. SKI-DLBCL-1 cells were exposed to each drug (10 nM) for 24 h, and were then exposed to the second drug for 24 h. &lt;ulink linkType="Drug" linkID="17990"&gt;Pralatrexate&lt;/ulink&gt; and subsequent &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; were determined to be the most cytotoxic combination (resulting in 22% of cells that were viable, compared with 100% for controls), followed by methotrexate and subsequent cytosine arabinoside (33% viable cells), &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and subsequent cytosine arabinoside (33% viable cells), and methotrexate and subsequent &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (68% viable cells). In corroboration with the results from the cytotoxic assay, apoptosis induction was higher in cells treated with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (~ 195% greater than in controls) than in cells incubated with methotrexate and cytosine arabinoside (~ 40%), &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and cytosine arabinoside (~ 135%) or methotrexate and &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (~ 100%). The combination of &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; followed by &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; induced the highest level of apoptosis (~ 290%), whereas &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; administered concomitantly with &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; was observed to be less effective (~ 45%), indicating that the sequence of administration may be important. When the drug combinations were assessed in SKI-DLBCL-1 xenografted SCID mice, four twice-weekly intraperitoneal doses of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; followed by &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (both 60 mg/kg) were determined to be superior to methotrexate (20 mg/kg) followed by cytosine arabinoside (150 mg/kg), resulting in average tumor volumes of 1500 and 2000 mm3, respectively, compared with 2500 mm3 in control animals [&lt;ulink linkType="Reference" linkID="650477"&gt;650477&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Further studies were performed to assess the combination of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; with the uricosuric agent probenecid. The extrusion of folate analogs is mediated by plasma membrane ATPases (most likely of the cMOAT/MRP [canalicular multispecific organic anion transporter/multidrug resistance protein] family) [&lt;ulink linkType="Reference" linkID="905307"&gt;905307&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905309"&gt;905309&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905310"&gt;905310&lt;/ulink&gt;]; probenecid has demonstrated an inhibition of the extrusion of the folate analog methotrexate from tumor cells [&lt;ulink linkType="Reference" linkID="905305"&gt;905305&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905306"&gt;905306&lt;/ulink&gt;]. BD2F1 mice xenografted with relatively chemoresistant murine Lewis lung cancer cells were administered four intraperitoneal injections of a saline control, &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (60 mg/kg), methotrexate (35 mg/kg), probenecid (125 mg/kg) or the combination of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; or methotrexate with probenecid (all at the same doses; administered concomitantly) every 3 to 4 days [&lt;ulink linkType="Reference" linkID="866856"&gt;866856&lt;/ulink&gt;]. Complete tumor regression was observed in 33% of mice that received the combination of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and probenecid, whereas none of the monotherapies or the combination of methotrexate with probenecid resulted in complete tumor regression; average tumor diameters following monotherapy with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;, methotrexate and probenecid were 7.9, 14.8 and 16.4 mm, compared with 16.2 mm in controls. The administration of probenecid in combination with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; or methotrexate reduced tumor diameters to 2.4 and 8.4 mm, respectively. &lt;ulink linkType="Drug" linkID="17990"&gt;Pralatrexate&lt;/ulink&gt; (60 mg/kg) as a monotherapy or combined with probenecid (125 mg/kg; both administered with the dosing schedule outlined in the previous study) was further evaluated in NCR-nu mice xenografted with LX1, A549, MX1 and prostate tumor PC3 and TSU-PR1 cells. The greatest responses were observed in LX1 and MX1 xenografts, in which complete regressions were observed in 67 and 75% of animals, respectively, after the combination therapy, compared with 17 and 25%, respectively, after &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; monotherapy. The combination resulted in reductions of &amp;gt; 90% in tumor size, compared with reductions of ~ 80% after monotherapy. In the other xenografts, complete regressions were noted following combination therapy (average of ~ 17%), but not with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; monotherapy; combination therapy similarly enhanced reductions in tumor diameter compared with monotherapy [&lt;ulink linkType="Reference" linkID="866856"&gt;866856&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In nude mice xenografted with JMN cells, no complete tumor regressions were observed following the administration of methotrexate and &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt; (both at doses of 40 mg/kg; four injections every 3 to 4 days), whereas complete regressions were observed in 17% of animals treated with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (60 mg/kg; four injections every 3 to 4 days) [&lt;ulink linkType="Reference" linkID="891822"&gt;891822&lt;/ulink&gt;]. The addition of probenecid (125 mg/kg; four injections every 3 to 4 days) to &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; treatment further improved the response (56% of animals displayed complete regressions). The average tumor diameter was reduced in all treatment groups, from 8.3 mm in controls to 5.6 mm with methotrexate, 4.8 mm with &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt;, 3.0 mm with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and 2.5 mm with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; plus probenecid [&lt;ulink linkType="Reference" linkID="891822"&gt;891822&lt;/ulink&gt;]. In a separate experiment, JMN xenografted mice received four injections of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (60 mg/kg), cisplatin (2 mg/kg), &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; (50 mg/kg), or the combination of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (45 mg/kg) with cisplatin (1.4 mg/kg) or &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; (35 mg/kg), every 3 to 4 days. Following monotherapy, only &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; was observed to cause complete regressions (in 11% of animals), whereas &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; in combination with cisplatin or &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; resulted in increases in complete regressions to 33 and 44%, respectively. The average tumor diameter was reduced from 10.1 mm in controls to 3.0, 5.1 and 5.5 mm following treatment with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;, cisplatin and &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt;, respectively, and was further decreased to 2.2 and 1.9 mm with the combination of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; with cisplatin and &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt;, respectively [&lt;ulink linkType="Reference" linkID="891822"&gt;891822&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;In mice, no adverse effects were observed for &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; at a dose of 60 mg/kg (established as the MTD), administered as four intraperitoneal injections every 3 to 4 days [&lt;ulink linkType="Reference" linkID="866856"&gt;866856&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="891822"&gt;891822&lt;/ulink&gt;]. No further toxicity data were available at the time of publication.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and pharmacokinetics&lt;/subtitle&gt;The pharmacokinetics of intraperitoneal &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (60 mg/kg) as monotherapy or in combination with intraperitoneal probenecid (125 mg/kg), administered as four doses once every 3 to 4 days, were assessed in mice xenografted with PC3 cells [&lt;ulink linkType="Reference" linkID="866856"&gt;866856&lt;/ulink&gt;]. In the first 2 to 3 h following treatment, plasma clearance was slower in animals receiving the combination (~ 5 microM of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; in the plasma at 2 h) than with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; monotherapy (~ 1 microM of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; in the plasma at 2 h), although the rate of clearance increased thereafter for the combination (at 6 h, the level of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; was ~ 0.07 microM with the combination and ~ 0.1 microM with monotherapy). The persistence of freely exchangeable &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (both parent and polyglutamylated forms) in the intracellular water of tumors was greater in mice receiving the combination than in those receiving monotherapy: an initially 2-fold greater level of intracellular &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; from the combination was increased to a 5-fold increased level within 3 to 7 h, indicating an enhanced net accumulation of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; in the tumor [&lt;ulink linkType="Reference" linkID="866856"&gt;866856&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase I clinical trial, 17 patients with solid tumors received intravenous &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (40 mg/m2) in combination with intravenous probenecid (70, 140 and 233 mg/m2) every 2 weeks. At the different dose levels of probenecid, the AUC, half-life and Cmax values of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; varied significantly among patients; for example, on day 1 in patients receiving &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; along with a dose of 140 mg/m2 of probenecid, the respective values ranged from 3.1 to 8.6 microg/ml.h, 1.1 to 5.9 h and 2.5 to 6.0 microg/ml. With increasing doses of probenecid, the mean AUC (4.9 to 6.2 microg/ml.h) and mean half-life (1.8 to 3.4 h) values of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; increased, whereas the mean Cmax values were 4.9, 4.7 and 6.7 microg/ml at doses of 70, 140 and 233 mg/m2 of probenecid, respectively [&lt;ulink linkType="Reference" linkID="866863"&gt;866863&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Following weekly and biweekly administrations of intravenous &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (escalating doses beginning from 30 mg/m2) to 33 patients with advanced NSCLC in a phase I clinical trial, mean AUC values after an initial dose of 30, 120, 130, 150 and 170 mg/m2 were 5.0, 8.2, 29.8, 20.6 and 30.6 micromol.h, respectively; the mean terminal half-life at a dose of 150 mg/m2 was 8 h. No changes were observed from the first dose to the second dose on the weekly or biweekly schedule. Chromatography analysis demonstrated the presence of a metabolite, which had a low peak level that did not change between day 1 and 15, indicating that no induction or inhibition of metabolism had occurred. Urinary excretion, measured in two patients, was 6 and 20% at 24 h [&lt;ulink linkType="Reference" linkID="866857"&gt;866857&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Pharmacokinetic data from 47 patients with hematological malignancies receiving intravenous &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; weekly (30 to 45 mg/m2) or biweekly (135 to 240 mg/m2) in a phase I/II clinical trial were modeled in a three-compartment linear model. Patient weight and methylmalonic acid (an indicator of vitamin B deficiency) were determined to be predictive of interpatient pharmaco-kinetic variability. Increased AUC levels for &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and methylmalonic acid were also predictive of toxicity. The pharmacokinetic model assisted in identifying the safest dosing schedule for &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;, and supported the need for vitamin supplementation (discussed in Clinical development section) [&lt;ulink linkType="Reference" linkID="858426"&gt;858426&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In a phase I clinical trial, 33 patients who had been treated previously for NSCLC received &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; intravenously at a starting dose of 30 mg/m2, administered weekly for 3 weeks in a 4-week cycle. This schedule was subsequently modified as a result of severe mucositis (described in Side effects and contraindications section; the term 'mucositis' appears to be used interchangeably in studies with 'stomatitis'): patients received escalating doses of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; beginning from 15 to 30 mg/m2, and increasing by 10 mg/m2 to a maximum dose of 170 mg/m2, administered every 2 weeks in a 4-week cycle [&lt;ulink linkType="Reference" linkID="288851"&gt;288851&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="327323"&gt;327323&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="866857"&gt;866857&lt;/ulink&gt;]. The MTD for the weekly regimen was 30 mg/m2, and was 170 mg/m2 for the biweekly regimen; a dose of 150 mg/m2 every 2 weeks was recommended as the phase II dose. Major clinical responses were observed in two patients: one patient (receiving a dose of 150 mg/m2) exhibited a 50% decrease in mediastinal adenopathy, and the other patient (receiving a dose of 170 mg/m2) displayed a complete regression of cervical lymphadenopathy after the first dose. On the weekly schedule, one patient exhibited stable disease for a duration of 7 months; on the biweekly schedule, five patients displayed stable disease for 7 months (with doses of 90 and 130 mg/m2), 9 months (80 mg/m2), 12 months (150 mg/m2) and 13 months (40 mg/m2) [&lt;ulink linkType="Reference" linkID="866857"&gt;866857&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Supplementation of methotrexate therapy with folic acid has been demonstrated to be beneficial in reducing methotrexate-induced side effects [&lt;ulink linkType="Reference" linkID="912308"&gt;912308&lt;/ulink&gt;]. A phase I, open-label, non-randomized clinical trial assessed whether supplementation of vitamin B12 and folic acid improved the MTD of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="842140"&gt;842140&lt;/ulink&gt;]. A total of 22 patients with NSCLC received intramuscular vitamin B12 (1 mg) and oral folic acid (1 mg) 7 days prior to receiving intravenous &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (150, 190, 230, 270 and 325 mg/m2) every 2 weeks. The addition of vitamin B12 and folic acid was determined to allow higher doses of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; to be administered: the MTD was increased to 270 mg/m2 [&lt;ulink linkType="Reference" linkID="842140"&gt;842140&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Based on the studies of the combination of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (and methotrexate) with probenecid, a phase I clinical trial was performed in 17 patients with solid tumors (53% with NSCLC) to assess the MTD of intravenous &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (40 to 60 mg/m2) administered every 2 weeks in combination with intravenous probenecid (70, 140 and 233 mg/m2) [&lt;ulink linkType="Reference" linkID="866863"&gt;866863&lt;/ulink&gt;]. The MTD at this schedule was determined to be 40 mg/m2 for &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and 140 mg/m2 for probenecid. An analysis of antitumor activity from this regimen in 16 patients revealed no objective tumor responses; 4 patients exhibited stable disease lasting 1.9 months (in a patient with NSCLC), 2.0 months (carcinoid tumor), 3.7 months (NSCLC) and 3.8 months (NSCLC) [&lt;ulink linkType="Reference" linkID="866863"&gt;866863&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In a phase I, open-label clinical trial, the MTD of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; in combination with &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; was evaluated [&lt;ulink linkType="Reference" linkID="514403"&gt;514403&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="806863"&gt;806863&lt;/ulink&gt;]. Out of the 48 patients in the trial, 43 had NSCLC, 2 had small-cell lung cancer, 1 had gastric carcinoma, 1 had thymic carcinoma and 1 had carcinoma of unknown primary. In the combination with intravenous &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; (175 mg/m2) administered every 2 weeks, intravenous &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (90 or 110 mg/m2) was administered every 2 weeks without vitamin supplementation; with intravenous &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; (35 or 50 mg/m2) every 2 weeks, intravenous &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (60 or 70 mg/m2) was administered every 2 weeks without vitamin supplementation; and with intravenous &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; (35 mg/m2) every 2 weeks, intravenous &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (80 to 140 mg/m2) was administered every 2 weeks with supplementation of intramuscular vitamin B12 (1 mg) and oral folic acid (1 mg) 7 to 14 days prior to treatment with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;. The MTDs were not established for the combinations without vitamin supplementation because of DLTs (described in Side effects and contraindications section), but the MTD of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; was determined to be 120 mg/m2 when combined with &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; and with prior vitamin supplementation. In 40 patients with NSCLC who received the &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; combination (with or without vitamin supplementation), 6 achieved a partial response, 20 had stable disease and 14 exhibited disease progression. The median progression-free survival (PFS) of the 40 patients was 4 months; 11 patients exhibited PFS for &amp;gt; 12 months, and 1 patient remained disease-free at 56 months. In six patients who received the combination of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt;, one patient with NSCLC and one with thymic carcinoma exhibited significant radiological responses that did not meet the criteria to be classified as partial responses; one patient with NSCLC continued to receive this drug combination for 9 months, and exhibited a 12-month duration to cancer progression [&lt;ulink linkType="Reference" linkID="806863"&gt;806863&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;At the time of publication, a phase I, non-randomized, open-label, multicenter clinical trial was recruiting patients with relapsed or refractory cutaneous T-cell lymphoma (expected n = 56) [&lt;ulink linkType="Reference" linkID="822207"&gt;822207&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905026"&gt;905026&lt;/ulink&gt;]. Patients would receive weekly, intravenous doses of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (30 mg/m2) for 2 or 3 weeks with vitamin B12 and folic acid supplementation. The primary endpoint of the trial would determine the effective and well-tolerated dose, and the secondary endpoint would characterize the safety profile of the regimen [&lt;ulink linkType="Reference" linkID="822207"&gt;822207&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905026"&gt;905026&lt;/ulink&gt;]. In interim data from 17 patients, 7 out of 14 evaluable patients demonstrated investigator-assessed responses, including two complete responses and five partial responses [&lt;ulink linkType="Reference" linkID="914014"&gt;914014&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I/IIa&lt;/subtitle&gt;A phase I/IIa clinical trial evaluated &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; in patients with hematological malignancies [&lt;ulink linkType="Reference" linkID="641143"&gt;641143&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="742175"&gt;742175&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="845166"&gt;845166&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="866860"&gt;866860&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="866861"&gt;866861&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="866865"&gt;866865&lt;/ulink&gt;]. In the initial part of the trial, 16 patients with Hodgkin's lymphoma, B-cell lymphoma, mantle cell lymphoma and peripheral T-cell lymphoma received &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; intravenously every 2 weeks at a dose of 135 mg/m2. As a result of mucositis-related adverse events (described in Side effects and contraindications section), the phase I portion of the trial was subsequently modified to a dose-escalation study, beginning at a dose of 30 mg/m2 weekly for 3 weeks in a 4-week cycle, progressing to 30 mg/m2 every week for 6 weeks in a 7-week cycle, and increasing by 15 mg/m2 on the 7-week schedule. On this revised schedule, 40 patients with Hodgkin's lymphoma, DLBCL and T-cell lymphoma were recruited (total n = 56 overall). The MTD on this schedule was determined to be 30 mg/m2 every week for 6 weeks in a 7-week cycle. In the most recent report of results for this trial, the overall response in 46 evaluable patients was 35% [&lt;ulink linkType="Reference" linkID="845166"&gt;845166&lt;/ulink&gt;]. In patients with B-cell and T-cell lymphoma (n = 20 and 26 evaluable patients, respectively), the overall response rates were 10 and 54%, respectively. Complete remissions were observed in nine patients with T-cell lymphomas, and partial remissions occurred in five patients and two patients with T-cell and B-cell lymphomas, respectively; the duration of remission ranged from 3 to 24 months. Durable complete remissions were observed in the following subtypes of cancer: acute lymphoblastic (12 months), human T-cell leukemia virus type 1 adult T-cell leukemia/lymphoma (&gt;/= 21 months; n = 3), blastic NK/T-cell lymphomas (8 months), anaplastic lymphoma kinase (+) anaplastic large cell (&gt;/= 10 months), peripheral T-cell lymphoma, not otherwise specified (3 months), subcutaneous panniculitis-like T-cell lymphoma (9 months) and gamma,delta-subcutaneous panniculitis-like T-cell lymphoma (9 months); most of the responding patients had been refractory to previous chemotherapy, including methotrexate [&lt;ulink linkType="Reference" linkID="845166"&gt;845166&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;At the time of publication, a phase I/IIa, non-randomized, open-label, multicenter clinical trial was recruiting patients with relapsed or refractory NHL (expected n = 84) to assess the combination of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="800746"&gt;800746&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905037"&gt;905037&lt;/ulink&gt;]. During the phase I portion of the trial, 54 patients would receive weekly, intravenous doses of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; beginning at 15 mg/m2, followed by &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; the next day beginning at a dose of 400 mg/m2 for 3 or 4 weeks, as well as vitamin B12 and folic acid supplementation. The primary endpoints would be determinations of the MTD, the recommended phase II clinical dose, safety and pharmacokinetics. In the phase II portion of the trial, an additional 30 patients would be treated, and the primary endpoints would be evaluated as tolerability and preliminary efficacy [&lt;ulink linkType="Reference" linkID="800746"&gt;800746&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905037"&gt;905037&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In a phase II clinical trial, 39 patients with stage IIIB or IV NSCLC, and either no previous chemotherapy, or progression after an initial response or stable disease following one previous regimen of chemotherapy, were treated initially with intravenous &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; at a dose of 150 mg/m2 every 2 weeks. Because of the rate of mucositis observed (described in Side effects and contraindications section), the initial dose was subsequently reduced: the first 29 patients received a dose of 150 mg/m2, and the other 10 patients received 135 mg/m2 [&lt;ulink linkType="Reference" linkID="410511"&gt;410511&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="495265"&gt;495265&lt;/ulink&gt;]. In 38 evaluable patients, 4 patients (receiving 150 mg/m2 of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and previously treated with chemotherapy) achieved a major objective response that lasted for 4, 9, 12 or 15 months, and 12 patients exhibited stable disease. Median survival was 13.5 months, and the predicted 1- and 2-year survival rates were 56 and 36%, respectively [&lt;ulink linkType="Reference" linkID="495265"&gt;495265&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase II clinical trial conducted in 16 patients with malignant pleural mesothelioma, participants were treated with intravenous &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; every 2 weeks at a dose of 135 mg/m2 [&lt;ulink linkType="Reference" linkID="891804"&gt;891804&lt;/ulink&gt;]. Nine patients did not receive vitamin supplementation unless mucositis developed, and the remaining patients received intramuscular vitamin B12 (1 mg) and oral folic acid (1 mg) 7 days prior to receiving &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;. No complete or partial responses were observed from the treatment, although two patients with tumors of epithelioid histology exhibited a minor reduction in tumor size (no further details were provided); however, this result did not meet the trial criteria for response. One of these patients remained in the trial for 31 months, and the other patient was removed from the study as a result of severe mucositis. Stable disease for 9, 9 and 48 months was also observed in three additional patients. The median time to progression was 3 months, the overall median survival was 7 months, and the 1-year survival rate was 31% [&lt;ulink linkType="Reference" linkID="891804"&gt;891804&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;At the time of publication, a phase II, non-randomized, open-label, multicenter clinical trial was ongoing in patients with relapsed or refractory peripheral T-cell lymphoma (expected n = 100; PROPEL [&lt;ulink linkType="Drug" linkID="17990"&gt;Pralatrexate&lt;/ulink&gt; in patients with Relapsed Or refractory PEripheral T-cell Lymphoma]) who received weekly, intravenous &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; at a dose of 30 mg/m2 for 6 weeks in a 7-week cycle, along with vitamin B12 and folic acid supplementation [&lt;ulink linkType="Reference" linkID="681536"&gt;681536&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905167"&gt;905167&lt;/ulink&gt;]. The primary endpoint was response rate, and the secondary endpoints included duration of response, PFS and overall survival [&lt;ulink linkType="Reference" linkID="905167"&gt;905167&lt;/ulink&gt;]. A recent safety review of 65 patients recommended the continuation of the trial [&lt;ulink linkType="Reference" linkID="863628"&gt;863628&lt;/ulink&gt;]; in April 2008, enrollment in the trial was completed [&lt;ulink linkType="Reference" linkID="898874"&gt;898874&lt;/ulink&gt;]. Interim data indicated that 29 out of 65 patients experienced either complete or partial responses [&lt;ulink linkType="Reference" linkID="906010"&gt;906010&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;At the time of publication, a phase IIb, randomized, open-label, multicenter clinical trial comparing the efficacy of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; with &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt; was enrolling patients with NSCLC (expected n = 160) who had previously failed treatment with at least one platinum-based chemotherapy regimen [&lt;ulink linkType="Reference" linkID="865389"&gt;865389&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905015"&gt;905015&lt;/ulink&gt;]. Patients would receive intravenous &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; every 2 weeks at a dose of 230 mg/m2 (increasing to 270 mg/m2 or decreasing to 190 mg/m2) or oral &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt; (150 mg/day). The primary endpoint was overall survival in patients treated with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; compared with &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt;; secondary endpoints included response rate, PFS and safety [&lt;ulink linkType="Reference" linkID="865389"&gt;865389&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="905015"&gt;905015&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Case study&lt;/subtitle&gt;A woman with a rare and highly aggressive CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor who had relapsed quickly after previous treatment with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy was treated with weekly, intravenous doses of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (30 mg/m2) every 4 weeks, supplemented with folic acid and vitamin B12. After six infusions, a durable response was observed and skin tumors regressed, indicating the potential use of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; for this malignancy [&lt;ulink linkType="Reference" linkID="883667"&gt;883667&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and contraindications&lt;/subtitle&gt;In a phase I clinical trial in 33 patients with NSCLC, weekly &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; in the initial 3-week cycle of the trial resulted in severe mucositis in 4 out of 6 patients [&lt;ulink linkType="Reference" linkID="288851"&gt;288851&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="327323"&gt;327323&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="866857"&gt;866857&lt;/ulink&gt;]. In patients receiving &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (15 to 170 mg/m2) every 2 weeks, grade 3 and 4 mucositis were observed in two patients receiving a dose of 170 mg/m2. In nine patients receiving &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; at a dose of 150 mg/m2, mucositis of grades 1, 2 and 3 was observed in two, two and one patient, respectively. Other common adverse events observed in the biweekly regimen were mild, including a grade 2 elevation of alanine transferase and aspartate transferase (n = 3), a diffuse maculopapular, pruritic skin rash (n = 1), and reticulonodular pulmonary infiltrates (n = 1). Significantly, no neutropenia was observed [&lt;ulink linkType="Reference" linkID="866857"&gt;866857&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;When &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; treatment was supplemented with vitamin B12 and folic acid in patients with NSCLC, no DLTs were observed at doses of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; of 150 to 230 mg/m2 [&lt;ulink linkType="Reference" linkID="842140"&gt;842140&lt;/ulink&gt;]. Grade 3 mucositis was reported in 5 out of 16 patients receiving the 270-mg/m2 dose and in 2 out of 3 patients receiving the 325-mg/m2 dose. Other common adverse events at all dose levels (n = 22) included grade 2 fatigue (n = 10), grade 1 nausea (n = 9), grade 1 vomiting (n = 4) and grade 1 rash (n = 4) [&lt;ulink linkType="Reference" linkID="842140"&gt;842140&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;When &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; was administered in combination with probenecid, 4 out of 17 patients discontinued treatment because of mucositis [&lt;ulink linkType="Reference" linkID="866863"&gt;866863&lt;/ulink&gt;]. In patients receiving the lower dose of probenecid (70 mg/m2; n = 3; median number of cycles = 2), grade 2 toxicities that each occurred in one patient were fatigue, anemia, peripheral edema, nausea, constipation, cough and hepatic pain; grade 1 rash was observed in two patients. In patients receiving 140 mg/m2 of probenecid (n = 9; median number of cycles = 1.5), grade 2 toxicities that each occurred in one patient were mucositis, nausea, fatigue and peripheral edema; two patients experienced grade 1 nausea, vomiting and diarrhea. At the highest dose (233 mg/m2; n = 5; median number of cycles = 2), grade 4 mucositis was observed in one patient, and three patients each experienced grade 2 or 3 mucositis [&lt;ulink linkType="Reference" linkID="866863"&gt;866863&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The three patients treated with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; (110 mg/m2) in combination with &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; developed dose-limiting grade 3 mucositis, which consequently resulted in a decrease of the administered dose to 90 mg/m2 in a further three patients; this revised dosage still resulted in dose-limiting grade 2 mucositis in one patient and grade 3 peripheral neuropathy in another patient [&lt;ulink linkType="Reference" linkID="514403"&gt;514403&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="806863"&gt;806863&lt;/ulink&gt;]. Among these six patients, two patients experienced clinically significant neuropathy; the combination of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; was not pursued further. &lt;ulink linkType="Drug" linkID="17990"&gt;Pralatrexate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; without vitamin supplementation caused dose-limiting grade 3 diarrhea in two out of three patients, leading to dose reductions of both agents; five patients subsequently exhibited no DLTs. Vitamin supplementation allowed for increased doses of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;; grade 2, 3 and 4 mucositis was experienced in patients receiving 120 or 140 mg/m2 of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; combined with weekly &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt;, while no cases of mucositis were observed at a dose of 120 mg/m2 &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; combined with &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; every 2 weeks. Common adverse events in patients receiving &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; with vitamin supplementation included grade 2 and 3 alopecia (n = 16), fatigue (n = 13) and neutropenia (n = 8) [&lt;ulink linkType="Reference" linkID="514403"&gt;514403&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="806863"&gt;806863&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase I/IIa clinical trial in patients with hematological malignancies, 135 mg/m2 of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; administered every 2 weeks was associated with cytokinetic failure, an increased risk of high-grade mucositis, and significant hematological toxicities, such as thrombocytopenia and leucopenia [&lt;ulink linkType="Reference" linkID="845166"&gt;845166&lt;/ulink&gt;]. When the dosing schedule was modified to weekly doses of 30 mg/m2 of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;, hematological toxicities were reduced by 50%, and no high-grade mucositis was observed [&lt;ulink linkType="Reference" linkID="845166"&gt;845166&lt;/ulink&gt;]. Vitamin supplementation also reduced the risk of mucositis [&lt;ulink linkType="Reference" linkID="742175"&gt;742175&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="845166"&gt;845166&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase II clinical trial in 39 patients with NSCLC, all of the 29 patients initially treated with 150 mg/m2 of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; experienced mucositis; mucositis of grade 0, 1, 2, 3 and 4 was observed in 4, 8, 11, 5 and 1 patients, respectively [&lt;ulink linkType="Reference" linkID="495265"&gt;495265&lt;/ulink&gt;]. When the dose was reduced to 135 mg/m2 (n = 10), grade 0, 1, 2, 3 and 4 mucositis occurred in 5, 0, 3, 1 and 1 patients, respectively. The remaining toxicities were mild, and most commonly included grade 1 and 2 fatigue (n = 23), nausea (n = 21), epistaxis (n = 19) and rash (n = 18). No clinically significant myelosuppression was observed [&lt;ulink linkType="Reference" linkID="495265"&gt;495265&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In a phase II clinical trial in 16 patients with malignant pleural mesothelioma, 3, 8 and 1 patients exhibited grade 2, 3 and 4 mucositis, respectively [&lt;ulink linkType="Reference" linkID="891804"&gt;891804&lt;/ulink&gt;]. Without vitamin supplementation, all patients (n = 9) developed at least grade 2 mucositis, whereas four out of seven patients receiving vitamin supplementation exhibited no mucositis, and the remaining three developed grade 3 mucositis. Other observed adverse events were mainly mild and of grade 1 or 2 severity; these effects included fatigue, alopecia and epistaxis in nine, six and five patients, respectively, who received no vitamin supplementation, and in six, one and four patients, respectively, who did receive vitamin supplementation [&lt;ulink linkType="Reference" linkID="891804"&gt;891804&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent summary&lt;/subtitle&gt;Since the mid 1970s, cancer researchers at &lt;ulink linkType="Company" linkID="20234"&gt;SRI International&lt;/ulink&gt; and the &lt;ulink linkType="Company" linkID="22122"&gt;MSKCC&lt;/ulink&gt;, notably Joseph I Sirotnak and Francis M DeGraw, have been studying the use of aminopterin derivatives as folate antagonists in the treatment of various tumors. Such derivatives include 10-alkyl-10-deazaaminopterins, as well as their 10-alkenyl, 10-alkynyl and 5,10-dideaza analogs. Early patents in this area include &lt;ulink linkType="Patent" linkID="IN1029389"&gt;US-04393064&lt;/ulink&gt;, which was filed in March 1976. More recent cases include a complex family of international applications filed by &lt;ulink linkType="Company" linkID="20234"&gt;SRI International&lt;/ulink&gt;, the &lt;ulink linkType="Company" linkID="22122"&gt;MSKCC&lt;/ulink&gt; and the &lt;ulink linkType="Company" linkID="20226"&gt;Southern Research Institute&lt;/ulink&gt; in the early 1990s (&lt;ulink linkType="Patent" linkID="IN2182948"&gt;WO-09322312&lt;/ulink&gt;, &lt;ulink linkType="Patent" linkID="IN2182951"&gt;WO-09322315&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="IN2182952"&gt;WO-09322316&lt;/ulink&gt;). One of the three issued US patents in this family, &lt;ulink linkType="Patent" linkID="IN2159363"&gt;US-05354751&lt;/ulink&gt; (issued from &lt;ulink linkType="Patent" linkID="IN2182948"&gt;WO-09322312&lt;/ulink&gt;), focuses on &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; in its exemplification, but the compound is not included in the claims. &lt;ulink linkType="Drug" linkID="17990"&gt;Pralatrexate&lt;/ulink&gt; appears to have been disclosed during the course of the research leading up to this March 1992 application, but was never actually claimed as novel. The &lt;ulink linkType="Company" linkID="20226"&gt;Southern Research Institute&lt;/ulink&gt; appeared to have assigned these patents to &lt;ulink linkType="Company" linkID="20234"&gt;SRI International&lt;/ulink&gt; and the &lt;ulink linkType="Company" linkID="22122"&gt;MSKCC&lt;/ulink&gt; by 1998, and ended its involvement in this area [&lt;ulink linkType="Reference" linkID="288851"&gt;288851&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 1996, &lt;ulink linkType="Company" linkID="20234"&gt;SRI International&lt;/ulink&gt; and the &lt;ulink linkType="Company" linkID="22122"&gt;MSKCC&lt;/ulink&gt; jointly filed &lt;ulink linkType="Patent" linkID="IN2433021"&gt;WO-09802163&lt;/ulink&gt;. This formulation case, claiming pure &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;, may constitute the most fundamental protection available. As of June 2008, the application was pending grant in Europe as &lt;ulink linkType="Patent" linkID="IN2472706"&gt;EP-00944389&lt;/ulink&gt;, although the filing of a divisional application (&lt;ulink linkType="Patent" linkID="PA3610282"&gt;EP-01891957&lt;/ulink&gt;) in February 2008 suggests that the granting of some of the subject matter is imminent. In the US, the formulation case proceeded more quickly to grant, issued first as &lt;ulink linkType="Patent" linkID="IN2721733"&gt;US-06028071&lt;/ulink&gt; with claims to the pure compound and its use in treating solid tumors (optionally in combination with a cytotoxic agent), then as &lt;ulink linkType="Patent" linkID="PA3124445"&gt;US-06323205&lt;/ulink&gt; claiming use with a taxane (eg, &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt;).&lt;/para&gt;&lt;para&gt;In May 2004, the &lt;ulink linkType="Company" linkID="22122"&gt;MSKCC&lt;/ulink&gt; filed a US application that led to &lt;ulink linkType="Patent" linkID="PA3067949"&gt;WO-2005117891&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3067950"&gt;WO-2005117892&lt;/ulink&gt;, with claims to treatment of T-cell lymphoma with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;, alone or in combination with &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;. At the time of publication, this family of applications contained no granted patents.&lt;/para&gt;&lt;para&gt;In &lt;ulink linkType="Patent" linkID="PA2910768"&gt;WO-2004081196&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; is mentioned as a possible active ingredient to be administered using a polymer implant claimed by &lt;ulink linkType="Company" linkID="14333"&gt;QLT USA Inc&lt;/ulink&gt;. Similarly, the use of the compound is mentioned by &lt;ulink linkType="Company" linkID="16629"&gt;Health Research Inc&lt;/ulink&gt; in &lt;ulink linkType="Patent" linkID="PA3213157"&gt;WO-2006074416&lt;/ulink&gt;, in a case concerned primarily with &lt;ulink linkType="Drug" linkID="2563"&gt;acadesine&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="19711"&gt;Schering-Plough Corp&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="814331"&gt;814331&lt;/ulink&gt;]). There are likely other mentions of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; in the patenting activity of companies not directly involved in the development of the drug. However, &lt;ulink linkType="Company" linkID="23253"&gt;Allos&lt;/ulink&gt;, the current licensee of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;, does not appear to have sought any additional patent protection for the drug in its own name.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current opinion&lt;/subtitle&gt;A major mechanism of tumor resistance to clinically useful antifolates, such as methotrexate, is based on the need of these compounds for polyglutamylation via FPGS. &lt;ulink linkType="Drug" linkID="17990"&gt;Pralatrexate&lt;/ulink&gt; was developed to improve membrane transport and intracellular accumulation, and preclinical studies have demonstrated that the drug was more efficiently transported into cells by RFC1 and was a more effective substrate for FPGS than either methotrexate or &lt;ulink linkType="Drug" linkID="3012"&gt;edatrexate&lt;/ulink&gt;. Enhanced polyglutamylation was observed in &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;-treated cells, resulting in the improved cytotoxicity of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; compared with other antifolates. &lt;ulink linkType="Drug" linkID="17990"&gt;Pralatrexate&lt;/ulink&gt; has demonstrated impressive activity in vitro and in vivo in several tumor types, including NSCLC, breast and prostate cancer, mesothelioma and lymphomas. &lt;/para&gt;&lt;para&gt;In T-cell lymphomas, &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; has demonstrated significant antitumor activity, particularly in patients with peripheral T-cell lymphomas. &lt;ulink linkType="Drug" linkID="17990"&gt;Pralatrexate&lt;/ulink&gt;, however, displays minimal activity in B-cell malignancies, including Hodgkin's lymphoma. The management of peripheral T-cell lymphomas has been largely extrapolated from the treatment of aggressive B-cell lymphomas; however, therapeutic responses to this approach are neither adequate nor durable for most patients with peripheral T-cell lymphomas. Limited success has been achieved in peripheral T-cell lymphomas with anthracycline-containing regimens; only a small fraction of patients on such regimens have experienced long-term survival [&lt;ulink linkType="Reference" linkID="906087"&gt;906087&lt;/ulink&gt;]. The CD25 subunit of the IL-2-receptor (a marker of T-cell differentiation) is expressed in a subset of patients with peripheral T-cell lymphomas [&lt;ulink linkType="Reference" linkID="906099"&gt;906099&lt;/ulink&gt;]. The fusion molecule of IL-2 to the diphtheria toxin &lt;ulink linkType="Drug" linkID="7237"&gt;denileukin diftitox&lt;/ulink&gt; (ONTAK) is marketed for patients with cutaneous T-cell lymphoma [&lt;ulink linkType="Reference" linkID="313866"&gt;313866&lt;/ulink&gt;]; limited reports have demonstrated tumor responses in patients with relapsed peripheral T-cell lymphomas [&lt;ulink linkType="Reference" linkID="857271"&gt;857271&lt;/ulink&gt;]. Recently, nucleoside analogs have been examined with interest for the treatment of this disease. &lt;ulink linkType="Drug" linkID="3199"&gt;Gemcitabine&lt;/ulink&gt;, for example, has demonstrated activity in relapsed peripheral T-cell lymphomas as a single agent [&lt;ulink linkType="Reference" linkID="906089"&gt;906089&lt;/ulink&gt;]. The combination of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; with &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; is currently being explored in a phase I/II clinical trial. If the results obtained with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; to date can be validated in ongoing phase I/II clinical trials and in phase III trials, &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; will have a secure niche for the treatment of T-cell lymphoma.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="17990"&gt;Pralatrexate&lt;/ulink&gt; has also exhibited activity in NSCLC. The potential role of the drug in combination with taxanes as a second-line treatment for NSCLC was explored. However, the field of second-line treatment for NSCLC already includes many candidates; multiple novel agents, such as tyrosine kinase inhibitors (eg, BIBW-2992, &lt;ulink linkType="Company" linkID="14881"&gt;Boehringer Ingelheim Corp&lt;/ulink&gt;; in phase III clinical development [&lt;ulink linkType="Reference" linkID="897890"&gt;897890&lt;/ulink&gt;]), VEGF receptor inhibitors (eg, &lt;ulink linkType="Drug" linkID="26495"&gt;vandetanib&lt;/ulink&gt;, &lt;ulink linkType="Company" linkID="1010444"&gt;Astra&lt;/ulink&gt; Zeneca plc; in phase III [&lt;ulink linkType="Reference" linkID="885096"&gt;885096&lt;/ulink&gt;]) and MEK kinase inhibitors (eg, ARRY-142886, &lt;ulink linkType="Company" linkID="14190"&gt;AstraZeneca plc&lt;/ulink&gt;; in phase II [&lt;ulink linkType="Reference" linkID="690303"&gt;690303&lt;/ulink&gt;]) are being tested in the clinic. For &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; to be incorporated into treatment protocols for NSCLC, the drug would need to prove clear superiority to established second-line agents such as &lt;ulink linkType="Drug" linkID="3536"&gt;pemetrexed&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt; in clinical trials [&lt;ulink linkType="Reference" linkID="906194"&gt;906194&lt;/ulink&gt;]; an ongoing phase IIb trial is currently comparing &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; with &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt;. &lt;/para&gt;&lt;para&gt;In the treatment of mesothelioma, the activity of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; as a single agent appeared to be lower than the activity observed with &lt;ulink linkType="Drug" linkID="3536"&gt;pemetrexed&lt;/ulink&gt;, which exhibited a 14% response rate in a phase II, single-agent clinical trial [&lt;ulink linkType="Reference" linkID="905866"&gt;905866&lt;/ulink&gt;]. &lt;ulink linkType="Company" linkID="23253"&gt;Allos&lt;/ulink&gt; appears to have discontinued the development of &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; for mesothelioma: this indication was no longer listed on the company's pipeline at the time of publication [&lt;ulink linkType="Reference" linkID="907518"&gt;907518&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Other antifolates have been associated with myelotoxicity. However, when &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; was administered along with vitamin supplementation, the drug was well tolerated; in contrast to the results observed with other antifolates, the lack of myelosuppression with &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; makes the drug an ideal agent for combination with other chemotherapeutic agents. Promising results have been obtained for &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; in combination with &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt;. Preclinical studies also indicated improved cytotoxicity for &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; in combination with &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;; as noted, this combination is currently undergoing a phase I/II clinical trial. &lt;/para&gt;&lt;para&gt;Several other antifolates are being developed without a requirement for polyglutamylation for antitumor activity; thus, these agents may be important competitors for &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt;. &lt;ulink linkType="Drug" linkID="6864"&gt;Plevitrexed&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="15266"&gt;BTG plc&lt;/ulink&gt;) was demonstrated to be effective and well tolerated in a phase I/II clinical trial for solid tumors [&lt;ulink linkType="Reference" linkID="759494"&gt;759494&lt;/ulink&gt;], and OSI-7904L (&lt;ulink linkType="Company" linkID="1017768"&gt;OncoVista Innovative Therapies Inc&lt;/ulink&gt;) was effective in a phase II clinical trial for solid tumors [&lt;ulink linkType="Reference" linkID="601685"&gt;601685&lt;/ulink&gt;]. However, these agents have not been tested in hematological malignancies, and &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; therefore has an advantage in this area of research. Additionally, &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; has received Orphan Drug status from the FDA and the &lt;ulink linkType="Company" linkID="22824"&gt;EMEA&lt;/ulink&gt; for the treatment of peripheral T-cell lymphoma [&lt;ulink linkType="Reference" linkID="680196"&gt;680196&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="785566"&gt;785566&lt;/ulink&gt;], and has also received Fast Track status in the US for this indication [&lt;ulink linkType="Reference" linkID="720943"&gt;720943&lt;/ulink&gt;]. At the time of publication, &lt;ulink linkType="Company" linkID="23253"&gt;Allos&lt;/ulink&gt; expected to make an NDA filing for &lt;ulink linkType="Drug" linkID="17990"&gt;pralatrexate&lt;/ulink&gt; in the treatment of peripheral T-cell lymphoma in the 'near future' [&lt;ulink linkType="Reference" linkID="903507"&gt;903507&lt;/ulink&gt;].&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1179286">Acrotech Biopharma LLC</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-01T00:00:00.000Z</StatusDate><Source id="2124997" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-01T00:00:00.000Z</StatusDate><Source id="1579590" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22730">Servier Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-11-01T00:00:00.000Z</StatusDate><Source id="2089348" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-30T00:00:00.000Z</StatusDate><Source id="1962812" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1598424" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1179286">Acrotech Biopharma LLC</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-01T00:00:00.000Z</StatusDate><Source id="2124997" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-03T00:00:00.000Z</StatusDate><Source id="1942971" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29750">Baxter Oncology GmbH</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-02T00:00:00.000Z</StatusDate><Source id="2107483" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-02T00:00:00.000Z</StatusDate><Source id="2107483" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="3466">Metastatic bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-05-29T00:00:00.000Z</StatusDate><Source id="1534042" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-05-29T00:00:00.000Z</StatusDate><Source id="1534042" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-05-29T00:00:00.000Z</StatusDate><Source id="1534042" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1754">Cutaneous T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-11-28T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1240">Mesothelioma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1754">Cutaneous T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="XE">South America</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3466">Metastatic bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3466">Metastatic bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3466">Metastatic bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1011">Esophagus tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3466">Metastatic bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-10T00:00:00.000Z</StatusDate><Source id="1190752" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1240">Mesothelioma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-01-07T00:00:00.000Z</StatusDate><Source id="475651" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-01-07T00:00:00.000Z</StatusDate><Source id="475651" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20226">Southern Research Institute</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-01-07T00:00:00.000Z</StatusDate><Source id="475651" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-01T00:00:00.000Z</StatusDate><Source id="2124997" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20234">SRI International</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-01-07T00:00:00.000Z</StatusDate><Source id="475651" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-01T00:00:00.000Z</StatusDate><Source id="2124997" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3466">Metastatic bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-10T00:00:00.000Z</StatusDate><Source id="1190752" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-01-07T00:00:00.000Z</StatusDate><Source id="475651" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23253">Allos Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-10T00:00:00.000Z</StatusDate><Source id="1190752" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-10-05T00:00:00.000Z</StatusDate><Source id="1047183" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-01-07T00:00:00.000Z</StatusDate><Source id="475651" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-10T00:00:00.000Z</StatusDate><Source id="1190752" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-01-11T00:00:00.000Z</StatusDate><Source id="1160474" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-01-20T00:00:00.000Z</StatusDate><Source id="1256450" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3466">Metastatic bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-10T00:00:00.000Z</StatusDate><Source id="1190752" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-01-20T00:00:00.000Z</StatusDate><Source id="1256450" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1598424" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1198465" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-10T00:00:00.000Z</StatusDate><Source id="1190752" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20226">Southern Research Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-12-31T00:00:00.000Z</StatusDate><Source id="420162" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-10-01T00:00:00.000Z</StatusDate><Source id="1500545" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-12T00:00:00.000Z</StatusDate><Source id="1753868" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-10-20T00:00:00.000Z</StatusDate><Source id="966212" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-10-20T00:00:00.000Z</StatusDate><Source id="966212" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-06-08T00:00:00.000Z</StatusDate><Source id="288851" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-01T00:00:00.000Z</StatusDate><Source id="1598600" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-31T00:00:00.000Z</StatusDate><Source id="1942971" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-05-29T00:00:00.000Z</StatusDate><Source id="1534042" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-01-20T00:00:00.000Z</StatusDate><Source id="1256450" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-08-31T00:00:00.000Z</StatusDate><Source id="1110266" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1754">Cutaneous T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-08-15T00:00:00.000Z</StatusDate><Source id="822207" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-01-07T00:00:00.000Z</StatusDate><Source id="475651" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-09-12T00:00:00.000Z</StatusDate><Source id="1174013" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1198487" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1011">Esophagus tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-07-31T00:00:00.000Z</StatusDate><Source id="1198478" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1198479" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-05-05T00:00:00.000Z</StatusDate><Source id="1096400" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3466">Metastatic bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-07-23T00:00:00.000Z</StatusDate><Source id="926651" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1754">Cutaneous T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-10T00:00:00.000Z</StatusDate><Source id="1190752" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-03T00:00:00.000Z</StatusDate><Source id="1942971" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22730">Servier Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-01-08T00:00:00.000Z</StatusDate><Source id="1908613" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-06-19T00:00:00.000Z</StatusDate><Source id="1673732" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1598424" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="XE">South America</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1598424" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-05-29T00:00:00.000Z</StatusDate><Source id="1534042" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22730">Servier Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-09-05T00:00:00.000Z</StatusDate><Source id="2069900" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22730">Servier Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-26T00:00:00.000Z</StatusDate><Source id="2110141" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20234">SRI International</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-12-31T00:00:00.000Z</StatusDate><Source id="420162" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-09-10T00:00:00.000Z</StatusDate><Source id="2070155" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-08-31T00:00:00.000Z</StatusDate><Source id="1198485" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-08-31T00:00:00.000Z</StatusDate><Source id="1198485" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-08-31T00:00:00.000Z</StatusDate><Source id="1198485" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-03T00:00:00.000Z</StatusDate><Source id="1942971" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24232">Spectrum Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-09-05T00:00:00.000Z</StatusDate><Source id="1320486" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-05-29T00:00:00.000Z</StatusDate><Source id="410511" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1240">Mesothelioma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-01-07T00:00:00.000Z</StatusDate><Source id="475651" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-01-07T00:00:00.000Z</StatusDate><Source id="475651" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-05-09T00:00:00.000Z</StatusDate><Source id="666224" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1240">Mesothelioma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-01-07T00:00:00.000Z</StatusDate><Source id="475651" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-08-29T00:00:00.000Z</StatusDate><Source id="686358" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-03-25T00:00:00.000Z</StatusDate><Source id="994735" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-09-25T00:00:00.000Z</StatusDate><Source id="1045006" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-21T00:00:00.000Z</StatusDate><Source id="1157245" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3466">Metastatic bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-07-23T00:00:00.000Z</StatusDate><Source id="1190909" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3466">Metastatic bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-07-23T00:00:00.000Z</StatusDate><Source id="1190909" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23253">Allos Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-04-29T00:00:00.000Z</StatusDate><Source id="1110266" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1753">Peripheral T-cell lymphoma</Indication><AwardedIndication>Treatment of relapsed or refractory periperal T-cell lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-09-24T00:00:00.000Z</MileStoneDate><Source id="1045038" type="PR"></Source></Row><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1753">Peripheral T-cell lymphoma</Indication><AwardedIndication>Treatment of relapsed or refractory periperal T-cell lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-03-24T00:00:00.000Z</MileStoneDate><Source id="994735" type="PR"></Source></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="319">Non-Hodgkin lymphoma</Indication><AwardedIndication>Treatment of T-cell lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-10-03T00:00:00.000Z</MileStoneDate><Source id="720943" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1045514">Mundipharma International Corp Ltd</OwnerCompany><Country id="JP">Japan</Country><Indication id="1753">Peripheral T-cell lymphoma</Indication><AwardedIndication>Peripheral T-cell lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-02-26T00:00:00.000Z</MileStoneDate><Source id="1530537" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1045514">Mundipharma International Corp Ltd</OwnerCompany><Country id="AU">Australia</Country><Indication id="1753">Peripheral T-cell lymphoma</Indication><AwardedIndication>For the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (nodal, extranodal and leukaemic/disseminated).</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-09-05T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="319">Non-Hodgkin lymphoma</Indication><AwardedIndication>Treatment of Hodgkinâs lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-10-01T00:00:00.000Z</MileStoneDate><Source id="1139850" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1754">Cutaneous T-cell lymphoma</Indication><AwardedIndication>Treatment of cutaneous T-cell lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="319">Non-Hodgkin lymphoma</Indication><AwardedIndication>Treatment of Hodgkinâs lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-07-16T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1754">Cutaneous T-cell lymphoma</Indication><AwardedIndication>Treatment of cutaneous T-cell lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-06-10T00:00:00.000Z</MileStoneDate><Source id="1108807" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="3466">Metastatic bladder cancer</Indication><AwardedIndication>Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-05-03T00:00:00.000Z</MileStoneDate><Source id="1100890" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1753">Peripheral T-cell lymphoma</Indication><AwardedIndication>Treatment of peripheral T-cell lymphoma (nodal, othe extranodal and leukaemic/disseminated)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-04-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3466">Metastatic bladder cancer</Indication><AwardedIndication>Treatment of advanced or metastatic relapsed non-papillary transitional cell carcinoma of the urinary bladder</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-02-28T00:00:00.000Z</MileStoneDate><Source id="992372" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1754">Cutaneous T-cell lymphoma</Indication><AwardedIndication>Treatment of cutaneous T-cell lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-02-03T00:00:00.000Z</MileStoneDate><Source id="1074614" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3466">Metastatic bladder cancer</Indication><AwardedIndication>Treatment of non-papillary transitional cell carcinoma of the urinary bladder</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-01-19T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3466">Metastatic bladder cancer</Indication><AwardedIndication>Treatment of non-papillary transitional cell carcinoma of the urinary bladder</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-11-05T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="316">B-cell lymphoma</Indication><AwardedIndication>Treatment of diffuse large B-cell lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-10-20T00:00:00.000Z</MileStoneDate><Source id="966212" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1753">Peripheral T-cell lymphoma</Indication><AwardedIndication>Treatment of peripheral T-cell lymphoma (nodal, othe extranodal and leukaemic/disseminated)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-12-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1753">Peripheral T-cell lymphoma</Indication><AwardedIndication>Treatment of peripheral T-cell lymphoma (nodal, othe extranodal and leukaemic/disseminated)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-04-13T00:00:00.000Z</MileStoneDate><Source id="785566" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23253">Allos Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1753">Peripheral T-cell lymphoma</Indication><AwardedIndication>Treatment of peripheral T-cell lymphoma (nodal, othe extranodal and leukaemic/disseminated)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-03-08T00:00:00.000Z</MileStoneDate><Source id="773572" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00605"><Name>DHFR</Name><SwissprotNumbers><Swissprot>O62583</Swissprot><Swissprot>P00374</Swissprot><Swissprot>P00375</Swissprot><Swissprot>P00376</Swissprot><Swissprot>P00377</Swissprot><Swissprot>P00378</Swissprot><Swissprot>P00381</Swissprot><Swissprot>P04753</Swissprot><Swissprot>P09503</Swissprot><Swissprot>P0A016</Swissprot><Swissprot>P0A017</Swissprot><Swissprot>P0C0P0</Swissprot><Swissprot>P0C0P1</Swissprot><Swissprot>P17719</Swissprot><Swissprot>P22573</Swissprot><Swissprot>P27421</Swissprot><Swissprot>P28019</Swissprot><Swissprot>P47470</Swissprot><Swissprot>P78028</Swissprot><Swissprot>P99079</Swissprot><Swissprot>Q07801</Swissprot><Swissprot>Q54801</Swissprot><Swissprot>Q59487</Swissprot><Swissprot>Q5HFZ7</Swissprot><Swissprot>Q5HPB1</Swissprot><Swissprot>Q60034</Swissprot><Swissprot>Q6G9D5</Swissprot><Swissprot>Q6GGY1</Swissprot><Swissprot>Q8NWQ9</Swissprot><Swissprot>Q920D2</Swissprot><Swissprot>Q9U8B8</Swissprot></SwissprotNumbers></Target><Target id="PTGT-03221"><Name>Folate receptor</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-08059"><Name>Folate transporter 1</Name><SwissprotNumbers><Swissprot>P41438</Swissprot><Swissprot>P41440</Swissprot><Swissprot>P42557</Swissprot><Swissprot>Q53S99</Swissprot><Swissprot>Q62866</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1041750">National Comprehensive Cancer Network</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1045514">Mundipharma International Corp Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1062207">Clinigen Group plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1179286">Acrotech Biopharma LLC</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14437">Baxter International Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15408">Choice Pharmaceuticals</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19863">Servier</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20226">Southern Research Institute</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20234">SRI International</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24232">Spectrum Pharmaceuticals Inc</Company><CountAsPrincipalActive>4</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>4</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>7</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>6</CountActive><CountInactive>0</CountInactive><CountTotal>6</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C#CCC(Cc1cnc2c(n1)c(nc(n2)N)N)c3ccc(cc3)C(=O)N[C@@H](CCC(=O)O)C(=O)O</Smiles></StructureSmiles><Deals><Deal id="113282" title="MSKCC to develop SRI's pralatrexate with Southern Research Institute"></Deal><Deal id="113283" title="Southern Research Institute to develop SRI's pralatrexate with MSKCC"></Deal><Deal id="113286" title="Allos to develop SRI's pralatrexate worldwide"></Deal><Deal id="128881" title="IDIS to conduct the named patient program for Allos Therapeutics' Folotyn outside of the US"></Deal><Deal id="129334" title="Allos to provide funding to NCCN to evaluate the role of pralatrexate in treating solid tumors and hematologic malignancies"></Deal><Deal id="130519" title="Choice Pharma to develop Allos' pralatrexate"></Deal><Deal id="134853" title="Mundipharma to codevelop Allos' pralatrexate worldwide outside the US, Canada, Turkey and Europe   "></Deal><Deal id="158032" title="Servier to develop and commercialize Spectrum's Zevalin, Folotyn, Beleodaq and Marqibo in Canada       "></Deal><Deal id="252867" title="Acrotech purchases Spectrum's portfolio of seven FDA-approved hematology/oncology products"></Deal><Deal id="252878" title="Mundipharma and Baxter Oncology to develop pralatrexate for peripheral T-cell lymphoma"></Deal></Deals><PatentFamilies><PatentFamily id="1290361" number="WO-2005117891" title="Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin"></PatentFamily><PatentFamily id="1309088" number="WO-09802163" title="Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors."></PatentFamily><PatentFamily id="2051565" number="WO-2009026234" title="Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer"></PatentFamily><PatentFamily id="2553622" number="WO-2013096800" title="Processes and intermediates for preparing pralatrexate"></PatentFamily><PatentFamily id="2588611" number="WO-2014187274" title="Pralatrexate and preparation method for intermediate thereof"></PatentFamily><PatentFamily id="2626525" number="WO-2013164856" title="A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof"></PatentFamily><PatentFamily id="2639809" number="CN-103274943" title="Pralatrexate intermediate and preparation method thereof"></PatentFamily><PatentFamily id="2646969" number="WO-2013177713" title="Process for preparation of an antifolate agent"></PatentFamily><PatentFamily id="2675379" number="WO-2014016740" title="Improved process for the preparation of pralatrexate"></PatentFamily><PatentFamily id="2677979" number="WO-2014020553" title="Salts of pralatrexate"></PatentFamily><PatentFamily id="2715425" number="CN-103588775" title="Epirubicin degradation impurities and its preparation method"></PatentFamily><PatentFamily id="2728540" number="WO-2014068599" title="Process for pralatrexate"></PatentFamily><PatentFamily id="2731386" number="CN-103739604" title="One suitable for industrial amplification production of epirubicin and preparation method"></PatentFamily><PatentFamily id="2867320" number="WO-2015021929" title="Combined application of isothiocyanate compound and anti-cancer medicine"></PatentFamily><PatentFamily id="2955667" number="CN-104628728" title="Preparation method of pralatrexate"></PatentFamily><PatentFamily id="3125212" number="CN-105272983" title="&lt;para&gt;High purity solid pralatrexate preparation method&lt;/para&gt;"></PatentFamily><PatentFamily id="3227907" number="CN-104418859" title="Crystal form of pralatrexate, medicine composition containing it and its prepare method and its application"></PatentFamily><PatentFamily id="3285716" number="IN-00308430" title="Preparation of pralatrexate used to treat relapsed or refractory peripheral t-cell lymphoma, comprises: e.g. treating 10-propargyl-4-deoxy-4-amino-10-deazapteroic acid with 2-chloro-4,6-dimethoxy-1,3,5-triazine in solvent with base"></PatentFamily><PatentFamily id="3482165" number="WO-2016205203" title="Combination therapy using belinostat and pralatrexate to treat lymphoma"></PatentFamily><PatentFamily id="3911019" number="CN-107488178" title="Preparation method for high-purity pralatrexate intermediate"></PatentFamily><PatentFamily id="3911026" number="CN-107488112" title="Preparation method of pralatrexate intermediate"></PatentFamily><PatentFamily id="4074989" number="CN-108069971" title="A refining method of pralatrexate intermediate"></PatentFamily><PatentFamily id="4085162" number="CN-108069970" title="A method for preparing pralatrexate"></PatentFamily><PatentFamily id="447435" number="WO-2011153368" title="Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin"></PatentFamily><PatentFamily id="464388" number="WO-09322312" title="Deazaaminopterins for treatment of inflammation."></PatentFamily><PatentFamily id="575214" number="WO-2012061469" title="Crystalline forms of pralatrexate"></PatentFamily><PatentFamily id="670652" number="WO-2011096947" title="Optically pure diastereomers of 10-propargyl-10-deazaaminopterin and methods of using same"></PatentFamily><PatentFamily id="77943" number="WO-2012021392" title="Methods for extending progression-free survival using 10-propargyl-10-deazaaminopterin"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>8</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>7</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>4</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lunan Pharmaceutical Co Ltd" id="1009275"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Shyndec Pharmaceutical Co Ltd" id="1015980"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gland Pharma Ltd" id="1027124"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Avra Laboratories Pvt Ltd" id="1030617"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shenzhen Neptunus Bioengineering Co Ltd" id="1031729"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alphora Research Inc" id="1044128"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China National Pharmaceutical Group Corporation" id="1055632"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sino Biopharmaceutical Ltd" id="1073089"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lianyungang Runzhong Pharmaceutical Co Ltd" id="1084090"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hetero Group" id="1087006"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Suzhou MiracPharma Technology Co Ltd" id="1095700"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lianyungang Hengyun Medicine Science &amp; Technology Co Ltd" id="1103487"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wuxi Jiexi Pharmaceutical Technology Co Ltd" id="1103508"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fresenius SE &amp; Co KGaA" id="13738"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ajinomoto Co Inc" id="13794"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Southern Research Institute" id="20226"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SRI International" id="20234"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Memorial Sloan-Kettering Cancer Center" id="22122"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Spectrum Pharmaceuticals Inc" id="24232"></CompanyLink><CountAsOwner>7</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Reddy's Laboratories Ltd" id="29387"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>